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Abstract 
 Post stroke depression (PSD) has been identified as the most prevalent psychiatric 
consequence of having had a stroke. Up to one third of all stroke survivors will experience 
depressive symptoms at some point during their recovery. When left untreated, PSD can be 
devastating to a stroke survivor’s rehabilitative process. The purpose of this Doctor of Nursing 
Practice project was to implement a PSD screening protocol at The Queen’s Medical Center 
(QMC) to address these potential issues. Objectives of this project included establishing an in-
patient PSD screening protocol at QMC, encouraging continuity of PSD screening in the 
outpatient setting, and increasing provider comfort discussing and screening for PSD. 
 Guiding this project from inception to finish was the IOWA model of evidenced based 
care. Through following the model’s steps, the project’s PSD team was able to create a 
standardized PSD screening protocol that was integrated into the workflow of QMC neurological 
intensive care unit providers. The protocol included the PHQ-2, which was used to screen all 
eligible patients with a primary diagnosis of stroke prior to their discharge.  
 Over a four-month interventional period 86 patients were screened with the new 
evidence-based protocol. Of those patients 61 were able to participate in the PHQ-2 screen. The 
prevalence of depressive symptoms in this group was 11.5%. This project was able to reach a 
93% provider screening compliance rate by project’s end. Survey results from providers as well 
as anecdotal provider feedback during team meetings showed an increase in provider comfort 
discussing and screening for PSD over the course of the interventional period. 
 Results of this project indicate that PSD, a condition typically poorly addressed, is a real 
concern in the Hawaiʻi population and that screening for it in the acute care setting is feasible. 
This project represents the first attempt at measuring a prevalence rate for PSD in a Hawaiʻi 
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acute care facility. Limitations of this project and its results include a limited interventional 
period, poorly validated depression screening tool for stroke patients, and decreasing hospital 
stays related to improved stroke care. Each of these may have contributed to the lower than 
expected prevalence rate for PSD in this acute care setting. 
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Chapter One. Executive Summary 
Introduction 
 This chapter is an introduction to the Doctor of Nursing Practice (DNP) project presented 
in this text. It begins with a discussion about the background of post stroke depression (PSD) and 
its consequences. The chapter then introduces the theoretical frameworks used, literature review 
and synthesis process, and the project’s proposed innovation and objectives. Following these 
sections is a brief overview of the methods utilized, results gathered, and a final discussion about 
the project. 
Background and Problem 
 Depressive symptoms are among the most prevalent behavioral health consequences of 
having had a stroke (Paolucci, 2008). The most consistently cited prevalence rate for the 
development of depression after stroke is 33% and comes from a 2005 systematic review by 
Hackett, Yapa, Parag, and Anderson. Untreated PSD is associated with increased hospital stays, 
delayed stroke rehabilitation, decreased quality of life, increased mortality risk, and an increased 
burden on the healthcare system (Hollander, 2014; Morris, Robinson, Andrzejewski, Samuels, & 
Price, 1993; Robinson & Jorge, 2016). These associations are profound given that many 
individuals with PSD go undiagnosed and therefore untreated (El Husseini et al., 2012; 
Herrmann et al., 2011). The purpose of this evidence-based project was to develop and 
implement a PSD screening protocol at The Queen’s Medical Center (QMC) to assess the 
prevalence of PSD and to mitigate its effects on stroke patient’s recoveries.  
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Conceptual Framework 
 This project included elements from three distinct conceptual models. The IOWA model 
of evidence-based practice, Rogers Diffusion of Innovation Theory, and the Centers for Disease 
Control and Prevention’s (CDC) framework for program evaluation. 
Literature Review and Synthesis 
 The databases PubMed, CINAHL, Cochrane Review, and Google Scholar were utilized 
to gather relevant literature pertaining to the purpose statement previously presented. After 
reviewing the abstracts of 382 articles, 28 were chosen for individual critique. The literature 
review was systematic and there were explicit inclusion and exclusion criteria utilized.  
Innovation and Objectives 
 Objectives of this project were to establish an in-patient PSD screening protocol in the 
QMC neurological intensive care unit, encourage continuity of PSD screening and care to the 
outpatient setting, and to increase provider comfort discussing and screening for PSD with their 
patients. The successful implementation of a standardized PSD screening protocol, that utilized 
the Public Health Questionnaire 2 (PHQ-2) prior to discharge, and the provision of educational 
in-services for providers helped fulfill these objectives. 
Methods 
Design 
 Guiding each step of this project was the IOWA model of evidence-based practice as 
described by Titler et al. (2001). Rogers’ (2003) Diffusion of Innovation model was additionally 
used to enhance the diffusion of this project’s innovation. A final and thoughtful evaluation of 
this project was then accomplished using the CDC’s framework for program evaluation. 
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Practice Change Description 
 Prior to this project QMC did not address the potential for PSD with a standardized 
screening protocol. To close this gap in behavioral health surveillance the PSD project team 
created a PSD screening protocol to assist QMC neurology intensive care unit (ICU) providers. 
During discharge, providers followed a PSD screening protocol that was integrated into their 
discharge summaries located in the electronic medical record (EMR). As per the protocol all 
patients were provided with verbal and written education regarding PSD. Patients were then 
screened with the yes/no PHQ-2 tool. When patients scored a 0 on the PHQ-2 the screening 
process would end and the interaction documented. Patients that scored greater than 0 would be 
offered a one-month SSRI prescription and have their primary care providers (PCP) notified 
directly. The interaction would then be documented in the discharge summary. 
Setting and Sample 
 QMC’s stroke program was the primary medical setting where data was collected for this 
project and included 12 neurology unit providers, the stroke program coordinator, and all 
neurology unit registered nurses (RN). During an average month in 2016 this team cared for 50 
patients with a primary diagnosis of stroke. 
 The target population for this project included all eligible patients with a primary 
diagnosis of stroke that were to be discharged by QMC neurological ICU providers. Exclusion 
criteria for this population included an inability to meaningfully participate in a PSD screening 
per provider judgment. Twelve providers were responsible for PSD screening over the four-
month intervention period during which time they screened 86 eligible patients. 
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Data Collection 
 The PSD team, using stakeholder feedback, created a comprehensive data management 
plan to ensure this project’s findings would be valid and credible. Data was predominately 
extracted from the EMR where patient discharge summaries were used to compile aggregate 
PHQ-2 results and protocol compliance rates. Data was reviewed at four intervals in a locked 
office by team members with proper authorization to access patient charts. Patient confidentiality 
was maintained through de-identification of all data prior to dissemination to PSD team 
members. 
Results 
 There were a total of 86 patients screened during this four-month project. Of those 86 
patients there were 61 that were able to participate in the PHQ-2 screening process. The positive 
screen rate for those 61 patients was 11.5%. Overall screening compliance in the provider group 
was 86%, however, over the last four weeks of the project compliance had reached 93%. 
Provider comfort discussing and screening for PSD increased steadily throughout this project as 
evidenced by an increase in pre and post intervention survey results as well as anecdotally via 
provider feedback during team meetings. 
Discussion 
 The purpose of this project was fulfilled through the successful creation and integration 
of a standardized PSD screening protocol into the workflow of QMC neurological ICU 
providers. Although a third of the prevalence rate reported in national data, the 11.5% prevalence 
rate found in this project shows that PSD is present in the Hawaiʻi population. Deficiencies in the 
screening tool utilized, short interventional period, and decreasing lengths of stay for stroke 
patients may partially explain the lower local prevalence rate. This project’s objectives of 
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increasing provider comfort with PSD and in achieving a 90% compliance rate were met. The 
objective of encouraging ongoing outpatient PSD screening cannot, unfortunately, be proven due 
to a lack of follow-up data. It is the hope of this project that outreach interventions targeting the 
outpatient providers had and will continue to have a positive effect on outpatient PSD screening 
rates. In summary, this project successfully implemented a standardized and evidence-based PSD 
screening protocol at QMC that helped to close an identified gap in care for stroke patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
Chapter 2. Problem 
Introduction 
 PSD, although widely unappreciated until recently, is a highly prevalent psychiatric 
consequence of having had a stroke (Towfighi et al., 2017). As is often the case, its 
consequences can be devastating to the rehabilitative process should recognition and treatment 
be delayed (Hollander, 2014; Robinson & Jorge, 2016). The purpose of this evidence-based 
project is to develop and implement a PSD screening protocol at QMC to address this potential 
problem. The following chapter will review the background of PSD and its consequences, 
describe the related body of literature with a critique and synthesis, and provide an evidence-
based practice change recommendation. 
Conceptual Model 
 The IOWA model of evidence-based practice was selected as the conceptual roadmap to 
guide the implementation of a PSD screening protocol for this Doctor of Nursing Practice 
project. As developed and described by Titler et al. (2001) and represented in Figure 1, the 
IOWA model is a systematic stepwise approach that guides clinicians in their pursuit to improve 
patient outcomes through the utilization of the current evidence base. The first step in this model, 
and a key feature that sets it apart from other evidence-based practice frameworks, is to identify 
the knowledge or problem focused clinical triggers that signal the need for a change in practice 
(Titler et al., 2001). Once triggers are identified, a practice change topic selected, and enough 
interest gained there remain six steps in the process: 2) forming a team, 3) literature search, 4) 
literature review and critique, 5) practice change recommendation, 6) piloting the change with 
evaluation and subsequent full-scale implementation, and 7) evaluation of project (Titler et al., 
2001). 
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Figure 1. The Iowa Model for Evidence-Based Practice as adapted from “The Iowa Model of 
Evidence-Based Practice to Promote Quality Care” by Titler, et. al, 2001. Critical Care Nursing 
Clinics of North America, 13(4), 497-509. Used/reprinted with permission from the University of 
Iowa Hospitals and Clinics, copyright 1998. For permission to use or reproduce, please contact 
the University of Iowa Hospitals and Clinics at 319-384-9098 . 
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Background and Problem 
 Individuals who have suffered a stroke are confronted with a life-changing event that has 
the potential to alter their biochemistry and challenge their psychological coping abilities. When 
these systems malfunction or are overwhelmed, the stroke survivor is at an increased risk for the 
development of various mood disorders beyond that of the general population (Paolucci, 2008). 
The most prevalent of these, associated as a consequence of having had a stroke, is the 
development of a depressive disorder (Paolucci, 2008). PSD, as is the accepted phrase, has been 
appreciated in the literature for nearly one hundred years (Robinson & Jorge, 2016). The 
emphasis on screening for and treatment of, however, has only recently gained attention. This is 
in part due to the fact that for many years PSD was thought to be an inevitable consequence of 
having had a stroke. 
 Beginning in the 1980’s, double blind randomized controlled trials (RCT) showing the 
efficacy of antidepressants in the treatment of PSD began to shift professional opinions on the 
issue (Robinson & Jorge, 2016). The increased interest in PSD and its potential to be addressed 
led to further studies that illustrated the detrimental effects of depression on stroke rehabilitative 
outcomes. Untreated PSD has since been associated with increased hospital stays, delayed stroke 
rehabilitation, decreased quality of life, and an increased burden on the healthcare system 
(Hollander, 2014; Robinson & Jorge, 2016; Towfighi et al., 2017). Perhaps most striking is that 
the presence of PSD has been associated with a 3.4 times increase in 10-year mortality following 
a stroke (Morris, Robinson, Andrzejewski, Samuels, & Price, 1993). These findings, including 
its treatability and potential for considerable harm, led more recent researchers to ask the 
questions of how prevalent is PSD and how can healthcare professionals screen for it?  
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 The most often cited prevalence rate for PSD is 33% and comes from a systematic review 
of case series and incidence reports performed by Hackett, Yapa, Parag, and Anderson (2005). 
Their pooled estimate was derived from national and international hospital, rehabilitative, and 
general population statistics and represents the prevalence of depressive symptoms at any given 
point in a 5-year post-stroke period. Work done by Ayerbe, Ayis, Rudd, Heuschmann, and Wolfe 
(2011) further suggest that although the point prevalence is generally accepted to be 33%, it is 
likely that up to half of all stroke survivors experience depressive symptoms at some point 
during that same time frame. This is partially explained by the differential development 
temporally of depressive symptoms post-stroke and that some courses of depression have been 
shown to resolve spontaneously (Hackett et al., 2005). It is worth noting that although 
spontaneous remission has been reported for PSD, the potential benefits of early treatment for 
those cases is ill addressed in the literature. 
 The anytime stroke prevalence in the state of Hawaiʻi during 2014, with a population of 
1,110,200 people, was 3.1% (95% CI 2.6 to 3.6; Hawaiʻi Health Data Warehouse, 2016). In 
Honolulu County on the island of Oahu where QMC is located, the stroke prevalence that same 
year was 3.3% in a population of 736,400 people (95% CI 2.6 to 4; Hawaiʻi Health Data 
Warehouse, 2016). If the accepted PSD prevalence rate is 33%, then it can be reasonably 
assumed that up 11,357 people in Hawaiʻi and 8,019 people in Honolulu County in 2014 were or 
became affected by depressive symptoms as a result of their stroke. These numbers are even 
more profound given that many individuals with PSD go undiagnosed and therefore untreated 
(El Husseini et al., 2012; Herrmann et al., 2011).  
 A secondary study of a multicenter prospective cohort registry by El Husseini et al. 
(2012) claims a possible missed detection rate of nearly 80% in all PSD cases. This was 
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determined by comparing positive Public Health Questionnaire 8 (PHQ-8) screens with the 
prescription of antidepressant medications at 3 and 12-month follow-ups. The study was not 
without limitations but is similar to the findings described by Herrmann et al. in 2011. In their 
study, just 4.8% of Canadian registry stroke patients were diagnosed with PSD. Using the 
generally accepted prevalence rate, the authors concluded that there was an apparent and 
significant gap in the detection of PSD (Herrmann et al., 2011).  
Baseline Data 
 Prior to this project’s intervention QMC did not screen for PSD in their inpatient stroke 
population. The number of patients screened prior to discharge in 2016, the latest year with 
available data, was in fact zero. They did and still do, however, do a brief screen with the PHQ-2 
and PHQ-9 within 1 week of discharge and again at 30 days via a telephone follow up call. 
Unfortunately, due to difficulties in reaching patients the follow up phone call success rate is 
rather low. Outpatient screening rates are even lower in the Queens Clinically Integrate 
Physician Network (QCIPN) where in 2016 just one screen was completed during 108 
encounters. Between 2011 and 2015 there were an average of 450 patients that were admitted to 
QMC with a primary diagnosis of ischemic stroke. Another 200 were admitted with a primary 
diagnosis of either intracerebral hemorrhage or subarachnoid hemorrhage. Of these patients, the 
average length of stay was 6.57 days and the average age was 69. The ratio of male to female 
patients was nearly equal.  
Project Triggers 
 Titler et al. (2001) describes two types of triggers that may signal the need for a practice 
change evaluation. Knowledge-based triggers include external signals to change that may come 
from new research or new guidelines. Problem-based triggers arise from internal clinical issues 
 11 
that can include quality improvement, financial burden, or risk management (Titler et al., 2001). 
This evidence-based PSD project includes both types of triggers as will be discussed. 
 TJC’s comprehensive stroke center certification requirement to screen for PSD was the 
initial impetus and first knowledge-based trigger for the consideration of this project. The second 
knowledge-based trigger, as discussed previously, came from an initial literature review that 
showed PSD contributes significantly to poor stroke-patient health outcomes (van de Weg, Kuik, 
& Lankhorst, 1999). Knowledge of the severity of consequences associated with untreated PSD, 
its prevalence rates, and the lack of adequate detection led to an initial recommendation to find 
the best evidence-based solution to screening for PSD in stroke patients at QMC.  
Search Strategy 
 The databases PubMed, CINAHL, Cochrane Review, and Google Scholar were utilized 
to gather relevant literature pertaining to the purpose statement presented. The search included 
combining the terms depression and stroke with screening, questionnaire, or survey. Additional 
search terms included systematic review, RCT, and PSD. Exclusion search parameters attempted 
to avoid literature pertaining to the treatment of PSD including intervention types and their 
effects. There were no limits set on the years of publication. After reviewing the abstracts of 382 
articles found searching each database, 28 were chosen for individual critique. This search was 
systematic and there were explicit inclusion and exclusion criteria used as mentioned above. 
Grading Tool 
 Melnyk’s Hierarchy of Evidence for Intervention Studies was utilized to organize and 
grade the critiqued articles. This tool ranks evidence into categories that include systematic 
review or meta-analysis (level I), RCT (level II), controlled trial without randomization (level 
III), case control or cohort study (level IV), systematic review of qualitative or descriptive 
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studies (level V), qualitative or descriptive studies (level VI), and expert opinions (level VII; 
Stillwell, Fineout-Overholt, Melnyk, & Williamson, 2010). Figure 2 represents the number of 
articles critiqued and their level of evidence.  
 
Figure 2. Number of articles reviewed and their corresponding levels of evidence. 
 
Literature Synthesis 
 The final body of literature synthesized here represents studies that address the specific 
instruments for the screening of PSD, their validity, when they should be administered, and 
considerations for non-verbal patients. A discussion of the overall quality, quantity, and 
consistency as well as the limitations of the body of literature is also presented.  
Post Stroke Depression Screening  
 Upon review of the body of literature, 24 different screening instruments utilized to 
capture PSD were identified. These instruments and the studies that utilized them are represented 
in Appendix A. Screening instruments were either self-administered, interviewer administered 
and scored, or a structured clinical interview by trained professional was conducted. The 
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instruments vary in their complexity from the 2-item PHQ-2 to the 28-item General Health 
Questionnaire. The four most recently studied instruments include the Beck’s Depression 
Inventory, Hamilton Anxiety and Depression Scale, Geriatric Depression Screen, and the Public 
Health Questionnaire 9 (PHQ-9; Meader, Moe-Byren, Llewellyn, & Mitchell, 2014, Level I). In 
the majority of studies utilizing the PHQ-9, the PHQ-2 was administered first as a pre-screening 
instrument. Considerations for choosing an appropriate instrument to be used in this evidence-
based project include how well the instrument is validated for the stroke patient population, the 
instrument’s ease of use, and the preferences of those utilizing the final PSD protocol. 
Validity and Cutoff Scores  
 To date, there is no screening instrument specifically designed and validated for the PSD 
patient population (Towfighi et al., 2017, Level IV). The majority of the literature presented here 
instead chose to attempt validation of currently accepted general population depression scales for 
stroke patients. Although methodologies varied considerably, the gold standard to achieve such 
validation in the literature was to compare the screening instrument’s results with a structured 
clinical interview utilizing the 3rd, 4th, or 5th Diagnostic and Statistical Manual of Mental Health 
Disorders as references (Berg, Lonnqvist, Palomaki, & Kaste, 2009, Level IV; de Man-van 
Ginkel, et. al, 2012, Level IV; Kang, et. al, 2012, Level 4; Lewis-Richter, Volz, Jobges, & 
Werheid, 2014, Level 4; Meader, et. al, 2014; Turner et. al, 2012, Level III). Given the potential 
for significant adverse outcomes associated with delayed diagnosis and treatment of PSD, a 
screening tool with the highest sensitivity is necessary.  
 The only meta-analysis represented in this body of literature pooled the sensitivity and 
specificity results of PSD screening instruments in all available studies having to do with PSD 
detection (Meader, et. al, 2014). Results of the analysis concluded that the Center for 
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Epidemiological Studies Depression Scale (sensitivity: 0.75; 95% CI 0.60 to 0.85; specificity: 
0.88; 95% CI 0.71 to 0.95), the Hamilton Depression Rating Scale (sensitivity: 0.84; 95% CI 
0.75 to 0.90; specificity: 0.83; 95% CI0.72 to 0.90), and the PHQ-9 (sensitivity: 0.86; 95% CI 
0.70 to 0.94; specificity: 0.79; 95% CI 0.60 to 0.90) were shown to be the three most reliable 
scales for detecting PSD (Meader et al., 2014).  
 Interestingly, the Meader et al. (2014) study found the multi-item PHQ-2 to underperform 
in the stroke patient population as compared to the primary care population (sensitivity 0.79; 
95% CI; specificity 0.76; 95% CI). The original yes/no version of the PHQ-2 has been poorly 
studied in PSD but did prove useful in an analysis of depression in 1024 participants with 
coronary heart disease enrolled in the Heart and Soul Study, of which 14% had a history of 
stroke (sensitivity 0.90; 95% CI; specificity 0.69; 95% CI; Towfighi et al., 2017). 
 An important consideration for any screening instrument is how to interpret the scores 
gathered. The cutoff values used to determine the potential presence for depression and its 
severity affect the sensitivity and specificity of the instruments used. For the majority of the 
studies pre-established instrument specific cutoff scores were utilized (Meader et al., 2014). The 
studies that chose to use different cutoff values did so to attempt to account for the overlapping 
somatic symptomology of stroke outcomes and depression. To do so, instruments that included 
somatic items were given higher cutoff values for depression. In general it was found that this 
reduced the overall reliability of the instruments (Kang et al., 2012). As for the PHQ-9, a cutoff 
value of greater than or equal to 10 was used to indicate depression in the majority of studies (de 
Man-van Ginkel et al., 2012, Level IV; El Husseini et al., 2012, Level IV; Hollender, K., 2012, 
Level V; Karamchandani et al., 2015, Level VI; Turner, et al., 2012; Williams, et al., 2005, Level 
II). 
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Timing   
 The appropriate time for an initial screening and subsequent interval screenings is 
unfortunately not answered directly by this body of evidence. There are instead four guidelines 
that simply recommend screening for mood disorders in post-stroke patients prior to their 
discharge from the hospital after acute event (Heart and Stroke Foundation of Ontario & 
Registered Nurses' Association of Ontario, 2011, Level VII; Intercollegiate Stroke Working 
Party, 2012, Level VII; Scottish Intercollegiate Guidelines Network, 2010, Level VII; VA/DoD 
Clinical Practice Guideline, 2010, Level VII). None of these guidelines reference evidence to 
support their recommendations in relation to mood disorder screenings nor do they offer advice 
as to follow up evaluations for depression in the outpatient setting. The remainder of literature 
represents studies with screening intervals ranging from within 5 days to 5 years post-stroke 
(Meader, et. al, 2014). For the purpose of this evidence-based intervention, the mandate by TJC 
to screen for PSD prior to discharge to qualify for comprehensive stroke certification will serve 
as the temporal guide.  
Non-Verbal Patients 
 Significant consequences of having a stroke include the inability to communicate 
verbally and the potential for severe cognitive impairment. Unfortunately, the majority of studies 
pertaining to PSD have eliminated these patients from their inclusion criteria. Represented in this 
body of literature are just four articles that attempted to validate or compare the validities of PSD 
instruments for the non-verbal stroke patient (Bennett & Lincoln, 2006, Level V; Bennett, 
Thomas, Austen, Morris, & Lincoln, 2006, Level V; Berg, et al, 2009; Hacker, Stark, & Thomas, 
2010, Level IV). The 3 instruments examined most thoroughly in these studies included the signs 
of depression scale, the stroke aphasic depression questionnaire, and the visual analogue mood 
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scale (VAMS). None of these scales have been adequately validated, however in the capacity 
that they have the VAMS scale outperformed the other two (sensitivity: 0.77; 95% CI; 
specificity: 0.82; 95% CI; Bennett & Lincoln, 2006). 
Body of Literature and Limitations 
 High-level studies with consistent methodologies are absent in the body of literature 
gathered and presented here in relation to PSD. The majority of the articles are cohort studies 
with convenience samples. Patient populations can rarely be generalized to the greater 
population and even less so to Hawaiʻi. Although the body of evidence appears to have an 
adequate quantity of studies, there are few that attempt to answer the same question. With 24 
different scales, there are few studies to compare with one another in relation to any one 
individual scale or setting. There were, however, enough studies for Meader et al. (2014) to run 
statistical analyses on the Center for Epidemiological Studies Scale, Hamilton Depression Rating 
Scale, and the PHQ-9 instruments. What this body of evidence lacks in quality it makes up for in 
consistency in relation to its reports on the prevalence of PSD, consequences of untreated 
depression, validity of the PHQ-9 instrument, and the conditions for which PSD should be 
screened. 
Evidence-Based Protocol 
 QMC requires a PSD screening protocol to continue to qualify as a comprehensive stroke 
center. This primary knowledge-based trigger was the impetus for synthesizing the body of 
literature related to PSD to develop an evidence-based intervention that would meet TJC’s 
guidelines and best serve each patient’s wellbeing. Given the continued lack of awareness about 
the prevalence and treatability of PSD, as evidenced by low detection rates, it was reasonable 
and prudent to implement an inpatient screening protocol at QMC (El Husseini et al., 2012; 
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Herrmann et al., 2011). The protocol serves to establish a mood baseline, refer patients to 
behavioral health as needed, and to begin the conversation with patient, patient’s family, and the 
healthcare staff about the potential for and serious consequences of untreated PSD. The 
following initial recommendation was a product of the literature review presented as well as on-
going QMC stakeholder feedback. 
Recommendation 
 Prior to discharge from QMC, a neurology unit provider will screen all eligible patients 
with a primary diagnosis of stroke for PSD using the yes/no PHQ-2 questionnaire. Although not 
yet consistently validated in the body of literature for the PSD population, the PHQ-2 is efficient 
enough to administer during a packed discharge workflow. Regardless of the score recorded, 
each patient and their family will be given an educational pamphlet and discussion regarding 
PSD. Patient and staff education that encourages ongoing surveillance for PSD will be the 
foundation of this intervention given that the body of literature shows a consistent and ongoing 
33% PSD prevalence rate through five years post-stroke (Hackett et al., 2005). 
 All PHQ-2 scores will be recorded in the patient’s discharge summary that will then 
follow them to their outpatient providers. Patients that score greater than 0 on the PHQ-2, 
indicating a potential for depression, will be encouraged to follow up with their PCP 
immediately for further evaluation (Meader et al, 2013). Using an electronic notification system 
each patient’s PCP will be notified directly of positive screening results. These patients will 
additionally be offered a one-month SSRI prescription to mitigate their increased risk for PSD 
during their transition in care. Each patient’s PCP and/or behavioral health specialist will 
determine ongoing SSRI use and need. The prescription of SSRIs to treat and possibly prevent 
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the development of PSD is supported by a meta-analysis by Juangco, Ang, Efendy, and Cuanang 
(2015; RR 0.36, 95% CI 0.22-0.60). 
  Should the patient endorse suicidal ideation, an immediate psychiatric consult will be 
ordered prior to the patient’s discharge. If the patient is unable to complete the PHQ-2 due to the 
consequences of their stroke, patient and family education will still be reviewed. There is 
currently no adequately validated non-verbal PSD screening instrument recommended by the 
literature. These patients and their family members will be encouraged to discuss the potential 
for PSD with their PCPs. The sum product of each of these interventions is a PSD screening 
protocol that establishes a conversation about, and baseline assessment of, ongoing PSD risk. It 
will do this by encouraging ongoing assessment in the outpatient setting through active 
communication between QMC and outpatient providers.  
Summary 
 This chapter has described the extent of the problem of PSD, provided a review, critique, 
and synthesis of the related body of literature, and outlined an evidence-based practice change 
recommendation to address PSD. This project will attempt to screen all eligible stroke patients 
for PSD prior to their discharge utilizing a validated depression-screening instrument. In doing 
so, the purpose of this project to develop and implement a PSD screening protocol at QMC will 
be fulfilled.  
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Chapter 3. Methods  
Introduction 
 Post stroke depression (PSD) is appreciated as a highly prevalent psychiatric 
consequence following an acute stroke event (Towfighi et al., 2017). When left undetected and 
untreated, PSD can have devastating consequences on a patient’s rehabilitative process 
(Hollander, 2014; Robinson & Jorge, 2016). The purpose of this evidence-based project was to 
develop and implement a PSD screening protocol at The Queen’s Medical Center (QMC) to 
address this potential problem. In the interest of designing and implementing a lasting and 
successful practice change, the IOWA model of evidence-based practice was selected as the 
conceptual roadmap to guide this project (Titler et al., 2001).  
 Figure 3 presents both the components of this project’s purpose statement and the 
outcomes associated with its objectives. As identified from the literature, there is a sizable gap in 
care for stroke patients that develop depression (El Husseini et al., 2012; Herrmann et al., 2011). 
This gap is in part due to a fundamental lack of appreciation related to the treatability of PSD and 
an absence of appropriate surveillance systems for it (Robinson & Jorge, 2016).  
 The main objectives of this evidence-based project, meant to address the needs of PSD 
patients and their families, were to establish an in-patient PSD screening protocol at QMC, 
encourage continuity of PSD screening and care to the outpatient setting, and to increase 
provider comfort discussing and screening for PSD with their patients. In this chapter the 
purposed practice change, a step-by-step IOWA model integrated implementation plan, and 
Center for Disease Control and Prevention (CDC) guided evaluation plan will be described. This 
chapter will then conclude with a review of resource needs, human subject considerations, and 
project limitations.  
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Figure 3. Problem (P), intervention (I), comparison (C), outcomes (O), and timing (T) statement 
utilized to formulate purpose statement and to guide literature review. 
 
Implementation Plan 
Overview 
 Within the scope of this project, the implementation of a PSD screening protocol at QMC 
included elements from three distinct conceptual models. Discussed in chapter 2, the IOWA 
model of evidence-based practice is the first of these and was chosen to be the master template 
and systematic step-wise guide. The second conceptual model, embedded within the 
implementation step of the first, is the Rogers Diffusion of Innovation Theory. Rogers (2003) 
P	 •  Of	all	stroke	patients	33%	develop	post	stroke	depression	and	up	to	80%	of	those	patients	may	go	undiagnosed.	(Hackett,	Yapa,	Parag,	&	Anderson,	2005;	El	Husseini	et	al.,	2012))	
I	 •  Evidence-based	PSD	screening	protocol.		
C	 •  Currently	no	practice	in	place	to	screen	for	PSD.	
O	 •  (1)	Number	of	patients	screened	for	PSD	(2)	Screening	compliance	rates	(3)	QCIPN	outpatient	screening	rates	(4)	Provider	comfort	screening	for	PSD	per	qualitative	surveys.	
T	 •  Intervention	period	of	four	months	with	PSD	screen	prior	to	hospital	discharge.	
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provides in his work considerations to improve the rate and success of adoption of a new 
innovation. The CDC’s framework for program evaluation is the third conceptual model and was 
chosen to direct the evaluation step of the IOWA model.  
Project Design 
 The rationale for choosing the IOWA model to implement a PSD screening protocol at 
QMC is that this was an EBP meant to guide evidence-based practice. This is an important 
distinction to make, as there are other project designs available to answer the same clinical 
question. Each of which, including research and quality improvement (QI) designs, have valid 
strengths and limitations. Here, both research and QI designs were excluded, as the former would 
not have fulfilled the temporal needs of this project’s objectives and the latter requires local data 
on an established process to improve outcomes (Newhouse, 2007). Considering this project’s 
objectives were to establish an intervention intended to meet the immediate needs of an 
organization and to close a recognized gap in care, it was prudent to choose an evidence-based 
project design. Evidence-based practice requires utilizing the best available evidence in 
conjunction with organizational priorities and patient preferences to solve clinical problems 
(Newhouse, 2007). 
Practice Change and Characteristics 
 In chapter 2, a review and critique of the literature informed the creation of a PSD 
screening protocol, the finalized version of which can be found in Appendix B. To summarize, 
the protocol involves screening all stroke patients at QMC for depression with the Public Health 
Questionnaire - 2 (PHQ-2) prior to their discharge and includes a step-by-step guide of 
interventions to be completed based on screening results. To encourage patient education and to 
facilitate the patient/provider conversation regarding PSD an educational handout was created 
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and integrated into the final screening protocol. The educational handout was translated into 
three languages, placed into patient admission packets, and can be found here in Appendix C.  
 In an effort to enhance this project’s chances of a successful implementation, 
consideration for Rogers (2003) five characteristics of a successful innovation was given 
throughout the creation process. Each of Rogers’ characteristics, as discussed in his Diffusion of 
Innovation Theory, are meant to decrease uncertainty about a new innovation and thereby 
increase its rate of adoption (Rogers, 2003). Rogers’ theory was chosen to aide in the 
implementation plan as both it and this project dealt with changing human behavior. 
 Relative advantage. To paraphrase Rogers (2003), the relative advantage of an 
innovation is defined as the degree to which something new is perceived as better than the thing 
it is meant to replace. In the case of this evidence-based project, the something new is the 
implementation of a PSD screening protocol and the something old is the absence of PSD 
screening altogether. Aside from the obvious advantage of doing something to address a clinical 
problem rather than not, the question of why screen at all could be proposed. For QMC, this 
potential question was answered by the fact that PSD screening prior to discharge is mandated by 
The Joint Commission (TJC) to maintain comprehensive stroke center status. More important 
reasons to screen for PSD include the fact that current practices of PSD screening are deficient 
and that untreated PSD is extremely harmful to a patient’s rehabilitative process (El Husseini et 
al., 2012; Towfighi et al., 2017). 
 Compatibility. Rogers (2003) describes compatibility as the degree to which a new 
innovation is consistent with a potential adopter’s values and needs. In the case of this project, 
the primary adopters will be the individuals administering the screening protocol. Secondary 
adopters will include the patient’s primary care and behavioral health providers, as they will be 
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the ones extending the care continuum started by QMC. Although the primary adopters will be 
mandated to carry out the screenings, the motivation for the innovation is consistent with the 
wellness-oriented values of QMC that each employee is meant to embody. 
 Complexity. Rogers (2003) discusses the characteristic of complexity and notes that the 
actual and perceived complexity of a new innovation is inversely related to its rate of adoption. 
This is where a discussion of which screening tool to use and why was helpful in formulating a 
finalized intervention. Integrating anything new into the workflow of a hospital staff member 
needs to consider ease of use, effectiveness, and efficiency. The PHQ-2 that has been chosen for 
this project may be administered by anyone, is partially validated in the stroke patient 
population, and takes less than five minutes to administer and document (Meader et al., 2014). 
Relative to other screening options, this is the least complex solution and most desired by the 
QMC neurology providers. 
 Trialability. Adopters appreciate trying innovations out prior to committing to behavior 
change (Rogers, 2003). This trialing period is consistent with the piloting the change step of the 
IOWA model that is apart of this project’s implementation plan. During the pilot stage, the PSD 
screening protocol will be initiated on a single unit. This will allow for user feedback and 
reinvention as needed. 
 Observability. The degree to which the results of an innovation are visible to others is 
the final characteristic discussed by Rogers (2003). The more visible, the faster adoption is 
thought to occur. This is the weakest characteristic of the project as the outcomes of the 
screening process are meant to prevent the negative repercussions of untreated PSD. To account 
for this barrier, the PSD screening protocol will be introduced to all staff, including Queens 
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Clinically Integrated Physician Network (QCIPN) providers, through educational sessions that 
highlight its importance. 
IOWA Model Integrated Strategy for Implementation 
 Each of the steps in the IOWA model of evidence-based practice change are discussed 
separately here as they relate to the implementation of a PSD screening protocol at QMC. As a 
review, the first step in the model is to identify clinical triggers that signal a need for change 
relating to a practice topic (Titler et al., 2001). Once triggers are identified, a practice change 
topic selected, and enough interest gained there remain six steps in the process: 2) forming a 
team, 3) literature search, 4) literature review and critique, 5) practice change recommendation, 
6) piloting the change with evaluation and subsequent full-scale implementation, and 7) 
evaluation of project (Titler et al., 2001).  
 Step 1. QMC is required to have a prior to discharge PSD screening protocol in place to 
retain their comprehensive stroke center certification. This primary trigger, considering their lack 
of a screening protocol, led the QMC stroke coordinator to select PSD screening as a topic in 
need of review. The weight of the requirement for a PSD screening and feedback given during 
their initial comprehensive stroke center review in October 2016 indicated that this topic was an 
organizational priority for QMC worth pursuing.  
 Step 2. According to Titler et al. (2001) the next step was to form a team to spearhead 
efforts to address the clinical topic selected. This was done through collaboration with the stroke 
coordinator in which all stakeholders and potentially interested contributors to the project were 
identified. Potential team members were approached in person and through electronic 
correspondence to assess interest and potential levels of involvement. This process led to the 
formation of the PSD screening protocol team that contributed to the final product.  
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 Step 3. With a topic selected and support garnered it was time to search all relevant 
literature. The Doctor of Nursing Practice (DNP) student compiled a final body of 28 articles that 
would be used to guide the production of a PSD screening protocol.  The details of the search 
strategy and results can be found in chapter 2. 
 Step 4. Once the evidence had been gathered it was then graded utilizing a standardized 
tool and sorted according to levels of evidence. This was done by the DNP student and presented 
to the group for review. During a multi-disciplinary team meeting early in the project, a decision 
was made that the evidence base was sufficient to move forward with the project.  
 Step 5. Moving along with the IOWA model it was time to create a preliminary 
recommendation for a practice change (Titler et al., 2001). This process required the integration 
of the best available evidence with QMC stakeholder values and clinician insight. To begin, a 
qualitative survey was sent out to all stakeholders of the project that would be directly 
responsible for the PSD screenings. The survey was accompanied by an email containing a brief 
review of the literature with findings that included a preliminary recommendation for a specific 
screening instrument. Questions addressed how the clinicians felt about the findings, what their 
real world experiences had been in regards to PSD, and how they felt the need for a screening 
protocol could be best addressed given all recent and relevant data.  
 The responses were critical in developing the final protocol. Feedback from all potential 
screeners was gathered and reviewed by the core PSD project team. Commonalities in the 
responses were given weighted significance in the design of the final protocol. With all relevant 
data, QMC values, and clinician input considered it was time to pilot the final recommendation. 
 Step 6. Titler et al. (2001) recommends piloting a practice change with evaluation prior 
to full-scale implementation. This period allows for reinvention to take place and is also 
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congruent with Rogers’ (2003) concept of allowing potential adopters the opportunity to trial a 
new innovation as a means of enhancing its chances of success. The final protocol created was 
piloted on a single QMC neurology unit for two weeks. Feedback from the screeners was then 
gathered throughout and reviewed by the PSD project team. Adjustments to the screening 
protocol’s interventions were made as needed and a full-scale implementation was conducted.  
 To enhance the project’s visibility educational sessions were held with staff RNs and 
providers to discuss PSD and its important implications regarding a stroke patient’s 
rehabilitation. Email reminders were sent out to reinforce the live date for the protocol and a 
poster was created and displayed in the pilot unit’s lounge. Every four weeks during the four-
month implementation period outcomes related data was reviewed and further adjustments to the 
program were made as needed.  
 Step 7. To ensure the program met its original objectives, a final evaluation of the project 
was conducted after the four-month intervention period. The template for the final evaluation 
was finalized prior to implementation using the CDC’s framework for program evaluation. 
Utilization of the CDC’s framework was intentional as it is designed to protect the validity and 
integrity of non-experimental projects. It does this with an emphasis on stakeholder input and 
four key standards that anchor the evaluation plan (Milstein & Wetterhall, 2000). These 
standards include feasibility, utility, propriety, and accuracy. The final evaluation involved 
comparing the data gathered during the implementation period with the defined CDC framework 
outcome measures to determine whether project objectives were met. The final evaluation has 
and will continue to guide the future of the PSD screening program as it grows. 
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Timeline 
 The timeline for activities related to the implementation through dissemination of results 
steps of this project are presented in figure 4. Activities presented represent critical steps that 
must be completed in the appropriate order prior to moving ahead. 
 
TASK 
2017 2018 
A M J J A S O N D J F M A M J 
Prepare & Submit QMC PI vs. 
Research Form (IRB) X               
Finalize Protocol with Core 
Stakeholder Group X               
Successfully Defend Proposal    X             
Final Core Stakeholder Group 
Meeting Prior To Live Date   X             
Create and Disseminate 
Marketing Resources  X X X            
QCIPN PSD Webinar Training   X             
Educate Staff  X X   X          
Develop Database   X              
Implement Practice Change     X X X X        
Data Collection and Entry     X X X X        
Implementation Data Review 
and Reinvention with Core 
Stakeholder Group 
    X X X X        
Final Data Entries         X       
Analyze Data         X       
Interpret Data/Write Chapters    X X X X X X X      
Oral Defense           X     
Graduation              X  
Prepare & Submit 
Dissemination Products               X 
Figure 4. Timeline of tasks to be completed from IRB approval through publication and 
dissemination of results.  
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Application of Users 
 Rogers (2003) discusses in his theory of innovation the need for the presence of a culture 
of change within an organization for the successful adoption of new practices. Individuals who 
believe in change, and are not stifled in their pursuit of it, are the ones who build this type of 
culture. They either have the authority to make that change happen or are willing to be the force 
of change as directed by others. These change agents and change champions respectively are 
fundamental to the success of any new practice change and examples of each can be found 
within this project. 
 The change agents for this DNP project include the QMC stroke program coordinator and 
QMC’s lead neurology research physician. Both are dedicated to the culture of change within 
their practice setting and are motivated by external mandates as well as a pension for what’s best 
for the patient. In addition to their forward thinking work ethic, both have the authority to 
mandate the changes they envision. Their support was crucial to the long-term success of this 
project.  
 In contrast to the change agents, the change champions of this project include those 
individuals who believe in change but do not have the direct authority to make final decisions. 
Change champions for this project include the PSD team’s data expert, DNP student, and two 
neurology unit providers who championed the project from its inception. These individuals were 
key in the early and rapid dissemination and adoption of this innovation. The two neurology unit 
providers, as well as one specific neurology unit RN, were the opinion leaders for this project. 
Opinion leaders are individuals that certain staff look to for assurance when faced with change 
and who have some measure of authority (Rogers, 2003). 
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Adopter Categories 
 Rogers (2003) describes a bell curve in relation to a new innovation that illustrates the 
cultural phenomenon of adoption within a larger group. The bell curve is divided into categories 
that each describes different people based on their willingness to adopt change. These categories 
include the innovators, early adopters, early majority, late majority, and laggards (Rogers, 2003). 
The classification of adopter categories assists the change agents to develop strategies specific to 
the needs of each group, thereby increasing the rate of adoption.  
Innovators. Innovators are those who are willing to experience new ideas with little to 
no encouragement (Rogers, 2003). They do so despite known potential failures and financial 
losses. For these reasons, this group requires the least amount of effort to convince that a change 
is worth adopting. As the implementation of a PSD screening protocol was mandated and so 
carries with it minimal risk, there was little opportunity to identify innovators in the case of this 
project. That being said, the stroke program at QMC has a healthy culture of change that is lead 
by their stroke program coordinator. 
Early Adopters. The majority of the PSD screening team could be considered early 
adopters as most of them hold leadership roles. Their attitudes about this innovation carried 
significant weight as they are looked upon by a majority of their staff as role models. Their 
positions gave them considerable influence over the rate of adoption of this PSD intervention.  
 As preventative innovations have few immediately visible benefits special consideration 
to Rogers’ (2002) article about preventative innovations was utilized to encourage the early 
adopters. These recommendations include eliciting ongoing feedback, reinforcing the 
innovations relative advantage, encouraging this group to actively promote the innovation to 
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their respective colleagues, and to reinforce the need for preventative services (Rogers, 
2002). 
Early Majority. This category consists of those individuals who are not in leadership 
roles but have influence over a large portion of the social network where an innovation is being 
introduced (Rogers, 2003). Within the scope of this project the early majority consists of the 
providers administering the screening tool and the RNs who care for stroke patients. As 
secondary users of the innovation, those not directly administering the screening instrument, the 
RNs’ attitudes about the intervention were important to consider. The RNs helped tremendously 
with patient education and in encouraging provider screening compliance. Staff educational 
sessions and feedback systems were also utilized to increase adoption in this category. 
Late Majority. The late majority includes those individuals who wait until most of their 
peers have trialed a new innovation prior to adoption (Rogers, 2003). To increase the rate of 
adoption by this group the same strategies for the early majority were utilized. Additionally, 
administrative mandates and surveillance of compliance were used to further encourage adoption 
for the late majority. 
Laggards. This group represents the last of the users to adopt a new innovation. Their 
hesitation is in part due to an entrenchment in tradition, closed social systems, and a lack of 
opinion leadership (Rogers, 2003). Laggards in this project include the outpatient providers who 
would be responsible for continuing PSD care post-discharge. These providers represent silos 
of care where each is socially isolated from the next, which limits the diffusion rate normally 
enhanced by social contact. Unfortunately, ongoing surveillance is one of the long-term 
objectives of this project and can only be completed by this group.  
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 One strategy used to reach a segment of this group was the creation and presentation 
of a PSD webinar that all QCIPN providers were invited to join. QCIPN providers receive 
credit for viewing these types of resources. The credit received is put towards increased 
reimbursement rates from Medicare and Blue Cross. This proved to be a very real incentive 
that helped to increase the rate of adoption in this project’s laggard group. Non-QCIPN 
providers were the most difficult to reach and their participation required ongoing 
attentiveness to the patient’s discharge note, direct provider communication per protocol, and 
an ongoing community dialogue about PSD. 
Social Systems 
 Diffusion of an innovation occurs through a social phenomenon and as such its rate is 
influenced by the characteristics of individual users (Rogers, 2003). The rate of diffusion of an 
innovation is additionally affected by the social systems in which it is being implemented. As 
defined by Rogers (2003), social systems are the interrelated units that are united in their joint 
problem solving of common goals. For this evidence-based project, the primary social system is 
the QMC stroke program, which includes the providers and RNs of QMC’s two neurology 
intensive care units. The secondary social system is the QMC organization that the first is 
embedded within. 
 QMC is a non-profit acute care medical facility founded in 1859 and located in Honolulu 
on the island of O‘ahu. Its primary mission is to provide high quality health care services to 
improve the well being of all people in Hawaiʻi (About the Medical Center, 2017). With over 
539 beds and nearly 3,600 employees QMC offers a full spectrum of services that range from the 
promotion of health and wellness to caring for Hawai‘i’s most critically ill (About the Medical 
Center, 2017). As a Magnet designated hospital, QMC is additionally invested in promoting 
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evidence-based practice throughout its organization. In addition to its large size, complexity, and 
interconnectedness, QMC’s organizational culture of innovation helped to facilitate a rapid 
diffusion of this project (Rogers, 2003). 
 QMC’s stroke program is the primary social setting where data will be collected for this 
project and includes 12 neurology unit providers, stroke program coordinator, and all neurology 
unit RNs. The program’s mission is to provide state-of-the-art medical care to patients with 
neurological diseases through the integration of clinical excellence, education, and research 
(About Us, 2017). The providers, who are a mix of physicians and APRNs, were the primary 
users of the proposed innovation and it was their compliance with the protocol and knowledge of 
PSD that was measured. During an average month in 2016 this team cared for 50 patients with a 
primary diagnosis of stroke. Although finalized protocols used to care for stroke patients at QMC 
are technically made using an authority structure, the stroke team providers report utilizing a 
consensus model to build proposed changes.  
Sample 
 The target populations for this project include all patients with a primary diagnosis of 
stroke and the providers that care for them. The accessible populations for data collection will 
include all patients with a primary diagnosis of stroke being cared for within QMC’s two 
neurological intensive care units and the 12 stroke program providers that care for them. 
Baseline data was collected just prior to implementation and represents screening rates for the 
previous twelve months. Post implementation data was then collected after the four-month 
intervention period. The final sample size for the stroke patient group was determined at the 
conclusion of the intervention phase of this project. With over 100 patients, the final sample size 
was adequate enough for a final evaluation. 
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 Inclusion criteria for stroke patients included those who were admitted with a primary 
diagnosis of stroke. Exclusion criteria for the stroke patients included an inability to participate 
in the screening per provider judgment. Inclusion criteria for the provider group included 
designation as a neurology unit provider. Exclusion criteria included those providers from 
disciplines outside of the neurology department. Although they represented a component of the 
stroke program’s social setting and aided in overall compliance with the protocol, the neurology 
unit RNs were apart of the data collection. 
Stakeholder Engagement Plan 
 Successfully implementing a lasting evidence-based intervention within the healthcare 
system requires a strong multi-disciplinary approach where all those affected by a new 
intervention are considered. Those individuals affected, including those involved in 
implementation and the primary users of the innovation, are considered stakeholders in the 
project (Milstein, Wetterhall, & CDC Evaluation Working Group, 2000). These stakeholders are 
valuable sources of input and are best integrated when they are actively identified and their 
values considered throughout the life of a project. The strategy of ongoing stakeholder 
engagement was used throughout this project and served to guide the three conceptual models 
utilized. 
 The CDC Framework for Program Evaluation, the conceptual roadmap guiding the 
evaluation step of the IOWA model, highlights the importance of stakeholder engagement in 
creating a credible and valid evaluation. Using the four CDC standards of utility, feasibility, 
propriety, and accuracy stakeholder input is gathered and synthesized into operationalized 
benchmarks through which the evaluation is filtered (Milstein et al., 2000). The four standards 
are presented in Figure 5. Without the collaborative effort of the stakeholder group to define both 
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what they would value in an intervention and how to judge the success of that intervention, a 
valid evaluation could not be completed. It is this formal agreement of judgment that is the 
defining feature of an evaluation that takes place in real time where the ability to control for all 
variables is absent (Milstein et al., 2000). 
 
 
 Figure 5. Definitions of each of the four CDC standards of program evaluation. Adapted 
from “A Framework Featuring Steps and Standards for Program Evaluation” by Milstein, 
Wetterhall, and CDC Evaluation Working Group, 2000, Milstein, Health Promotion Practice, 3, 
p. 221–228. 
 
 Stakeholder engagement, as just described in the CDC’s framework for evaluation, is 
equally important to the IOWA and the Rogers Diffusion of Innovation models. Step two of the 
Utility 
•  Ensures that the information gathered matches the needs of the evaluation 
users. 
Feasiblity 
•  Ensures that the evaluation is viable and can be carried out in a timely 
manner. 
Propriety 
•  Ensures that the evaluation is ethical and that the rights of all those 
invovled are protected. 
Accuracy 
•  Ensures that the findings are correct in relation to the agreed upon 
judgments of the stakeholder group. 
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IOWA model requires forming a team to carry out a project to address an identified clinical 
problem (Titler et al., 2001). Identifying those individuals, or stakeholders, affected by the 
clinical problem and actively involving them in the decision making process greatly enhances the 
success and effectiveness of a proposed intervention (Titler et al., 2001). Stakeholders can 
further be characterized by their potential willingness to adopt the proposed intervention. 
Intentionally including stakeholders from each of Rogers (2005) adopter categories, with a 
consideration of their corresponding traits, can help facilitate a rapid diffusion of a proposed 
intervention.  
 The initial core stakeholder group responsible for the implementation and evaluation of 
this project included the QMC stroke program coordinator and DNP student. It was through 
these two that step one of the IOWA model, identifying the clinical problem, was initiated. Once 
the need for a PSD screening protocol was identified, additional stakeholder input was actively 
sought out during a monthly multi-disciplinary stroke team meeting in October 2016. QMC’s 
data management expert and their lead neurology research physician both expressed interest 
during the initial meeting where the project was announced and became the next stakeholders to 
be included in the PSD team. Brainstorming sessions conducted through in-person meetings, 
phone calls, and emails helped to identify the final core stakeholder roster.  
 The core stakeholder group consists of those individuals who are considered most 
instrumental to the successful implementation of this PSD project. Importance of each 
individual, along with his or her input and effort, was determined using principles from the 
IOWA model, Rogers Diffusion of Innovation Model, and the CDC’s Framework for Program 
Evaluation (Titler et al, 2001; Rogers, 2005; Milstein et al., 2000). Taking from Titler et al. 
(2001), stakeholders in positions to make organizational level decisions were included given 
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their ability to set organizational priorities. From Rogers (2005) model, stakeholders who were 
considered opinion leaders and change champions were also included due to their ability to 
encourage the rapid diffusion of the project and their authority to enact change. The CDC’s 
framework further helped to both identify different types of stakeholders as well as offered 
suggestions for how to gather and integrate their input to ensure reliable results. 
 Initial engagement strategies included the use of a CDC interests and support worksheet 
that helped to determine the level of involvement each member wanted. Additional CDC tools 
helped to identify what each stakeholder valued most and what their ideas of a successful 
implementation were. Throughout this project stakeholder input from the core group was 
continually sought after in all decision-making as well as during the implementation and 
evaluation phases of this project. This was done through the use of email based surveys, group 
emails, monthly in-person PSD team meetings, and informal dialogue in the clinical setting. All 
other stakeholders affected by the intervention were engaged through the use of mass media and 
interpersonal communication channels as suggested by Rogers (2005). 
Application of Communication Processes 
 Rogers’ (2005) diffusion of innovations model is the guide through which the 
implementation step of this project was conducted. Part of implementation, as discussed by 
Rogers (2005), is the processes through which new information is shared with those adopting an 
innovation. Strategic use of these processes, or communications among stakeholders, requires a 
combination of strategies. The importance of any given strategy depends upon where in the 
implementation phase a project is and who the target audience is meant to be. As discussed in the 
previous section, ongoing stakeholder engagement throughout the life of this project was 
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fundamental to its success. Engagement involved the use of both mass media and interpersonal 
communication channels as described by Rogers (2005). 
 Mass Media. Mass media communication channels are meant to reach individuals that 
represent many different groups of potential users. They are also effective in creating awareness 
about a change, which is beneficial in gaining the support of innovators and early adopters 
(Rogers, 2005). Providing information to all those affected by a change is additionally beneficial 
in the knowledge stage of the innovation-decision process as described by Rogers (2005). For 
these reasons the initial stage of implementation for this project included the use of mass emails, 
unit poster boards, a QCIPN webinar, and regular stroke program announcements. Just prior to 
and during the implementation of this project email surveys were sent to the primary users of the 
intervention for ongoing feedback related to operational concerns. After the implementation and 
evaluation of this project was completed, results were disseminated through public forums, mass 
emails, and stroke program announcements.  
 Interpersonal Communication. Whereas mass media is effective at generating an initial 
sense of awareness related to a proposed change, it is through interpersonal communication that 
decisions about adoption are made and kept (Rogers, 2005). One on one, preferably in-person, 
conversations about the details and opinions of an intervention are crucial during the persuasion 
stage of the innovation-decision process (Rogers, 2005). It is important to have a strategy in 
place to steer the conversation during implementation in a positive direction and to allow for 
feedback by all those affected to be heard. This was achieved through actively encouraging the 
previously described change champions and change agents to engage their peers and employees. 
This allowed for positive reinforcement to flow outward into the greater stakeholder group and 
for concerns to be voiced back to the PSD team. Additional interpersonal communication 
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strategies utilized included in-person staff training, monthly PSD team meetings, and informal 
weekly on-unit check-ins with primary users. 
Evaluation Plan 
 To ensure this evidence-based implementation project met its defined outcomes related 
objectives an evaluation plan was created. The evaluation plan presented in the following 
sections was designed using the CDC framework for program evaluation (Millstein & 
Wetterhall, 2000). Each step of the framework was followed using consistent and ongoing 
stakeholder feedback that was purposefully solicited to ensure the integrity and validity of this 
project’s findings (Millstein & Wetterhall, 2000). To guide the evaluation step of the IOWA 
model and to focus the evaluation plan for this project an evaluation question was created.  
 The evaluation question reads will the introduction of a provider administered evidence-
based PSD screening protocol increase the percentage of eligible patients with a primary 
diagnosis of stroke screened and appropriately referred for depression to 90% prior to discharge 
in the neurological intensive care units at QMC over a three-month period? Using SMART 
criteria, each component of the evaluation question was carefully selected so that specific 
operational definitions of each could be created. Very specific operational definitions, as 
mutually agreed upon by the core stakeholder group, are crucial in the creation of an evaluation 
plan that has outcomes that are measurable. SMART criteria used to craft the evaluation question 
are defined in Figure 6.  
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Figure 6. S.M.A.R.T. criteria components defined and clarified. 
 
Integrity of Evaluation Design 
 The CDC’s framework for program evaluation is anchored by four standards that are 
meant to help ensure that the integrity and validity of an evaluation design are maintained. As 
discussed previously in the stakeholder engagement section, it does so with an emphasis on 
stakeholder input (Milstein, Wetterhall, & CDC Evaluation Working Group, 2000). The four 
standards of utility, feasibility, propriety, and accuracy, previously presented in figure 1, help 
focus the input of the stakeholder group and the evaluation design as a whole. Judgments and 
values related to each standard are eventually synthesized into a formal agreement that clearly 
states what is meant to be measured, operationalized outcome measures, what a successful 
implementation looks like, and how evaluation data is to be used and disseminated. The 
integration of ongoing stakeholder input with consideration for the CDC’s four standards help 
ensure that the validity and integrity of a project that is taking place in real time are maintained 
(Milstein et al, 2000). 
S 
•  Specific - What is being measured? 
M 
•  Measurable - Can it be measured? 
A 
•  Assignable - Who will do it? 
R 
•  Realistic - Can intended results be achieved given time and resources? 
T 
•  Time-related - When are results to be obtained? 
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 To answer the evaluation question of this project a mixed process and impact evaluation 
design was utilized to help describe how a PSD screening protocol will impact the lack of 
appropriate screening of QMC patients whom were admitted with a primary diagnosis of stroke. 
Consideration for the four CDC standards was critical in maintaining the integrity of this 
project’s evaluation design.  
 Utility. Utility has to do with ensuring that evaluation plan results will be useful and 
relevant to the needs of the stakeholder group (Milstein et al., 2000). For this project, the 
stakeholders have defined utility as evaluation results that are able show the TJC that screening 
compliance has been achieved, that PSD screening captures the majority of eligible patients, and 
that appropriate protocol interventions have been carried out. The stakeholder group further 
identified the need for this data to be gathered and presented prior to the next TJC review in early 
2018. The stroke program coordinator and the neurology providers will actively use the results of 
this evaluation to maintain their comprehensive stroke center designation and to further develop 
post stroke behavioral health monitoring programs. 
 Feasibility. An evaluation plan is deemed feasible if all planned evaluation activities can 
realistically be carried out given available resources (Milstein et al., 2000). During stakeholder 
engagement meetings it has been emphasized that the final PSD protocol needs to be simplistic 
and easy to integrate into the workflow of neurology unit providers. Outcomes related data also 
needs to be easy to extrapolate from patient health records and all results need to be presented 
prior to the end of 2017. It was the consensus of the group that the implementation and 
evaluation plans were feasible given the proposed timeline and availability of support. 
 Propriety. Propriety has to do with ensuring that all ethical concerns are considered. A 
major concern of all stakeholders, especially those involved in administration, was that the rights 
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of all participants of the project were protected. These rights included the protection of patient 
and provider health related information. To avoid a breach in participant rights, all data was 
reviewed by the stroke program coordinator in a locked office and de-identified prior to 
dissemination to the PSD team for further analysis. There was no need to collect or present data 
with patient identifiers.  
 Accuracy. The CDC defines accuracy as the ability of an evaluation to produce valid 
results that answer the questions of those who need them (Milstein et al., 2000). The accuracy of 
this evaluation was maintained through engaging all stakeholders in the analysis and 
interpretation of project results. Initial stakeholder engagement produced operationalized 
definitions of what a successful implementation looks like and how to measure that success. In 
relation to the main concern of all stakeholders, that stroke patients be screened for PSD, 
outcomes data related to screening rates of all eligible stroke patients was collected during the 
implementation phase. This data helped answer the evaluation question, which reflects the values 
and judgments of the core stakeholder group.  
Program Description 
 QMC’s comprehensive stroke program’s purpose statement includes the provision of 
state-of-the-art medical care to patients with neurological and neurosurgical diseases through the 
integration of clinical excellence, education, and research (About Us, 2017). QMC’s 
comprehensive stroke program does this through adhering to an exhaustive list of guidelines and 
competencies as mandated by TJC. These guidelines, which can be found in Appendix D, 
include meeting performance measures that relate to the delivering of care to stroke patients from 
the time they arrive to the hospital through their discharge and follow up. This project’s 
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evidence-based intervention tied into the provider’s discharge process of QMC’s stroke program 
patients within the 4D and 5D stroke units at QMC. 
 Prior to discharge, providers are required to complete a final assessment of their stroke 
patients, conduct patient education, and ensure that all discharge plans are finalized. The 
operational workflow related to this process begins the evening prior to discharge by a night shift 
nurse practitioner (NP). The night shift NP completes a discharge summary draft, reviews 
educational content, and goes over the treatment plan with the patient and their families. The 
morning of discharge the neurology unit physician assigned the patient to be discharged does a 
final round with the patient to answer any remaining questions. The final step involves the 
physician answering any remaining questions by the patient and their families and the 
submission of a finalized discharge summary. 
 From the patient and patient’s family’s perspective, this process can be overwhelming 
due to the acute stroke event and the amount of information being received. This potential 
problem of information overload and an overwhelming of a patient’s ability to cope with their 
situation is further exacerbated by decreasing lengths of stay for stroke patients in the inpatient 
setting. Patients are presented with discharge instructions related to follow-ups, rehabilitation, 
and medications. They are further educated about long-term anticoagulant therapy, potential for 
future strokes, community resources, and general stroke related information.  
 Prior to this project QMC did not address the potential for the development of depression 
after having had a stroke. The need for such patient education and for a screening protocol was 
identified in the literature as previously discussed. Also discussed, and the main trigger for this 
project, is the mandate by TJC for comprehensive stroke center designation of having a prior to 
discharge PSD screen.  
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 The intervention carried out in this project was designed to add a layer of behavioral 
health surveillance that was missing and to address the project’s main triggers. Although the 
discharge workflow was already saturated for QMC neurology providers, the integration of an 
easy to use PSD screener was important and necessary given an overall lack of screening. The 
addition of the PHQ-2 to the discharge process helped allow QMC’s stroke program to retain 
their comprehensive stroke center designation as well as to mitigate the potential consequences 
of depression on stroke patient rehabilitation.  
 The protocol additionally attempted to help patients beyond their inpatient stay, as it 
required providers to communicate PSD screen results to outpatient providers in their discharge 
summaries and via secured personal communications. All positive screens were offered an SSRI 
prescription for one month with instructions to follow up with their primary care providers 
and/or neurology specialist. The prescription of an SSRI helped act as an additional bridge of 
surveillance for depression as the outpatient providers were responsible for ongoing assessments 
of SSRI need. Ultimately, this intervention required a small addition of effort on the part of 
QMC neurology providers to add a large benefit to stroke patients and their health related 
outcomes. 
Evaluation Plan Definitions 
 Prior to the design of an evaluation plan the core stakeholder group must carefully 
consider and agree upon the definitions of each project component (Millstein & Wetterhall, 
2000). Definitions relating to the problem being addressed, the proposed intervention, baseline 
data, evaluation type, desired outcomes, and the sample population are presented here in their 
conceptual and operational forms. The first of which is the problem being addressed and is 
conceptually defined as an identified need to screen for depression in all stroke patients. The 
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operational definition includes the need to screen for PSD in all eligible patients with a primary 
diagnosis of stroke at QMC to maintain comprehensive stroke center designation by TJC.  
 To address this clinical problem a PSD screening protocol was created. The evidence-
based intervention included the use of the PHQ-2 followed by a third question relating to a 
patient’s desire to be on an SSRI. The protocol included guidelines for specific interventions 
related to the assessed severity of the patient’s depressed mood. Titler et al. (2001) includes 
defining the comparison intervention that a proposed change is meant to replace in her IOWA 
model. A comparison intervention is what an institution is currently doing to address the same 
clinical problem as the one being addressed. In the case of this project the comparison 
intervention was the absence of any standardized behavioral health screening in stroke patients at 
QMC.  
 Evaluation of this evidence-based PSD screening project was done using a process and 
impact design. An impact evaluation allowed the PSD team to determine the effect of the 
intervention on the target population through an analysis of outcomes related data (Center for 
Disease Control and Prevention, 2014). To bolster the validity of the impact evaluation, a 
process evaluation was also conducted to ensure that the protocol was implemented as intended 
and that the results being gathered were applicable to desired outputs (Center for Disease Control 
and Prevention, 2014). The process evaluation further served as a feedback channel during the 
initial implementation phase so that changes to the protocol could be made as needed. To help 
measure the overall impact of the intervention baseline data, or data collected prior to a practice 
change, was collected. Baseline data for this project included the percentage of eligible patients 
screened for PSD and referred as needed during the previous year prior to the implementation of 
this project. 
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 Outcomes are defined as the intended impacts of an intervention and can be divided into 
process and impact ones. Process outcomes are those that identify whether or not an intervention 
is being implemented as intended. The conceptual definitions for this project’s process outcomes 
included an increase in provider comfort discussing and screening for PSD as well as accuracy of 
completed screens. These definitions are operationalized as an increase in provider comfort 
discussing and screening for PSD as measured by qualitative survey results, the achievement of 
90% of eligible patients being screened appropriately during implementation, and 90% accuracy 
of completed screens. The first process outcome represented a mediating factor in the overall 
success of this project. Mediating factors are those forces in a project’s implementation that may 
adversely affect the intended outcomes. Ensuring providers are aware of PSD and how to screen 
for it helped mitigate this mediating factor. 
 Impact outcomes were those outcomes that helped identify whether the goals of the 
intervention were met and what effect the intervention had. Conceptual definitions for these 
outcomes included the percentage of eligible patients screened for PSD and the actual PHQ-2 
screening results. As with the process outcome the project’s impact outcome related to screening 
compliance hoped to achieve an overall 90% screening rate by intervention’s end. The screen 
results did not have a specific goal but would instead inform further research and practice 
changes related to PSD. During the initial implementation phase preliminary data reviews helped 
trigger meaningful conversations with the providers administering the screening tool to see what 
barriers they were facing. This helped ensure the intervention was being implemented as 
intended.  
 For the purpose of this project, those that were included in the project’s implementation 
were defined as the sample populations. Inclusion criteria for this project’s sample included 
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those patients with a primary diagnosis of stroke that were admitted to a QMC neurology unit 
during a four-month implementation phase. Exclusion criteria included those patients that could 
not participate in a depression screen as determined by the neurology unit providers. A second 
sample worth clearly defining in relation to this project’s outcome measures includes the 
providers responsible for administering the intervention. Inclusion criteria for this group included 
those providers at QMC that work in the neurology units.  
Data Management Plan 
 Step 4 of the CDC’s framework for program evaluation includes the process of gathering 
credible evidence (Millstein & Wetterhal, 2000). This step was started in the previous section 
with the careful and purposeful creation of definitions relating to the components of this project’s 
evaluation question. Once the definitions were crafted and desired outcomes operationalized, the 
PSD project team created a data management plan (DMP) that formally outlined how data would 
be handled for this project. As with each step of this project, stakeholder input was once again 
critical. Including stakeholders in the DMP helped ensure that the evaluation question was 
answered using techniques that were considered credible by all those eventually utilizing the 
evaluation plan’s results. Millstein & Wetterhall (2000) illustrate this point in their discussion of 
how a collectively constructed DMP can help avoid credibility issues relating to defining 
outcomes, quality of data, data sources, and the logistics of data gathering. 
 Data quality is the cornerstone of ensuring that an evaluation of a project produces 
credible, reliable, and valid results as interpreted by stakeholders. Without accounting for 
quality, an evaluation runs the risk of gathering data that does not directly measure the thing it is 
meant to measure. To help ensure that the data gathered in this project is informative to the 
evaluation question, the PSD team discussed many factors that could potentially influence data 
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quality. Factors discussed and considered in the final DMP included the complexity of data 
gathering procedures, complexity of data gathered, where data would be gathered from, and 
appropriate training of all individuals gathering data. As will be described in more detail, this 
DMP’s strongest asset is its simplicity.  
 To further ensure the credibility of this project’s evaluation, data sources were carefully 
selected. The data sources were categorized according to whether they would provide process or 
impact related data. The first process outcome required a data source that would measure 
whether provider comfort discussing and screening for PSD had been enhanced. Pre and post 
qualitative survey responses from the QMC neurology unit providers were analyzed to provide 
the appropriate data.  
 Providers were additionally graded during implementation to determine their compliance 
with the protocol. The data source for this, which was additionally an impact related data source, 
was the EMR at QMC. The EMR provided access to provider discharge summaries. The specific 
data elements being measured were the PHQ-2 results from each patient’s discharge summary as 
well as the providers PSD care plan. The PHQ-2 and care plans were standardized using a dot 
phrase that providers used during their discharge visits. A final analysis of data from this source 
helped answer the project’s primary evaluation question of whether 90% of eligible stroke 
patients were being screened for PSD prior to discharge from QMC neurology units. 
 Prior to implementation an educational in-service with the neurology unit providers was 
conducted. Once the implementation was rolled out the PSD team’s data management expert and 
the stroke program coordinator collected data every four weeks. They both accessed patient 
charts, which they used to record the number of eligible stroke patients that were screened for 
PSD. They additionally recorded, in a yes or no fashion, whether the protocol’s interventions 
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were carried out appropriately. Data was de-identified and aggregated prior to dissemination to 
the PSD team. Both data collectors had prior authorization to access patient charts and did so in 
their locked offices to ensure patient confidentiality. 
 Analyzing the data gathered was the final step in the DMP and helped inform the 5th step 
of the CDC’s framework for program evaluation that includes justifying all conclusions 
(Millstein & Wetterhall, 2000). As mentioned previously, this DMP benefited from its 
simplicity. There is one process outcome and just two well-defined outcome related measures 
that two well-qualified PSD team members were responsible for gathering data on. As the data 
related to the impact measures was gathered it was added to a spreadsheet for final analysis. 
Individual spreadsheet pages corresponded to four-week implementation intervals. Columns on 
each page included patient gender, if patient was eligible for screening, whether patient was 
screened, whether screen was complete, results of screen, whether SSRI was prescribed, whether 
patient education was complete, and additional comments. 
 Throughout the analysis of data the PSD stakeholder group was included. This was 
accomplished at interval in-person meetings with the core stakeholder group and during a final 
multi-disciplinary stroke team meeting. Data was compiled into a presentation designed to show 
the results of each data measure. A discussion then followed to analyze the findings, how they 
answered the evaluation question, and to consider alternative meanings behind the results. The 
final discussion of the data prior to the dissemination of results helped ensure the final product 
was credible, valid, and useful. 
Project Resources 
 Successfully implementing this EB project required considerations for the resources 
available to it within the QMC system. Without the appropriate finances, individual effort, time, 
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and physical resources this intervention could not be operationalized. Utilizing the notion of 
stakeholder feedback from both the IOWA model and the CDC’s framework for program 
evaluation, determinations about resource needs were been made through consensus agreements 
(Titler et al, 2001; Millstein, Wetterhall, & CDC Evaluation Working Group, 2000). Input was 
actively sought out from stakeholders during team meetings, emails, and online surveys.  
 Financial. Fortunately for this project, the finances needed to implement EBP initiatives 
within the QMC stroke units had already been allocated in the annual budget for 2016. The 
budget made room for staff training hours, cost of changing the EMR, and money for media 
campaigns. A preliminary submission for the proposed change was approved and finances 
allocated.  
 Human Capital. Identifying, designing, implementing, and evaluating a new 
intervention requires the effort of many individuals to successfully complete. During initial 
stakeholder meetings estimates of the level of human input required were made. To make sure 
that the needed effort was available a CDC stakeholder engagement tool was utilized. The tool 
required each stakeholder to mark his or her level of preferred involvement. Based on data from 
this tool and further meetings with the core stakeholder group it was determined that the effort 
needed was available and that it would not tax the stroke program beyond its capacity. 
 Time. A timeline of activities related to implementation was created and agreed upon by 
all stakeholders involved with the intervention. Part of the creation of the timeline was a 
discussion about potential barriers to a successful implementation and whether there was time to 
adjust as needed. The final consensus was that a four-month implementation period would be 
ample time to change the behaviors within the stroke program as needed for the PSD screen to be 
a success.  
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 Physical. The only two physical resources required by this project include a space to 
collect, synthesize, and store outcomes data and wall space for the mass media campaign. Both 
resources were identified. Data was stored in the stroke program coordinator’s locked office and 
each of the two units volunteered wall space for poster presentations.  
Dissemination Plan 
 The final step of the CDC’s framework for program evaluation involves ensuring that the 
results and lessons learned from a program evaluation are used (Millstein & Wetterhall, 2000). 
Consideration for this step was integrated into each of the previous steps of this project to help 
design an evaluation plan that would be useful and approachable for the target stakeholder 
audiences. These audiences included members of the QMC stroke program, QMC neurology unit 
providers, and TJC. Dissemination plans for each audience were similar but were created 
separately to account for the different needs of each group.  
 Findings interpreted from data gathered during this project’s implementation period were 
put together into graphical content. The graphical content was included into a power point 
presentation that was presented at the January 2018 multi-disciplinary stroke team meeting. This 
meeting provided an opportunity for the PSD project team to disseminate their results to the 
representatives of all departments involved in the QMC stroke program. Copies of the power 
point were sent out to these representatives and further dissemination was encouraged within 
their respective departments. This face-to-face interaction encouraged rapid dissemination of the 
results throughout the QMC organization (Rogers, 2003). 
 QMC’s neurology unit providers were addressed separately during their regularly 
scheduled monthly meeting in January 2018. Disseminating results directly to this group of 
stakeholders was crucial as it will be through their behavior change that the new PSD protocol is 
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maintained. The presentation included many of the same elements as the multi-disciplinary team 
meeting power point but also included an emphasis on sustainability. Reinforcement of the 
project’s success was included, as was a discussion about further improvements and 
responsibilities.  
 The primary trigger of this project was the need for a prior to discharge PSD screening 
protocol to maintain comprehensive stroke center designation at QMC. To ensure this need was 
met the results of this evaluation were additionally tailored to TJC. Outcomes related content 
was made available for TJC as they eventually determine whether QMC has fulfilled the PSD 
screening mandate. To enhance the visibility of the PSD screening protocol, the PSD team also 
produced an executive summary of the project. This summary includes a discussion of the 
project’s methods and results. The executive summary was also disseminated to all QCIPN 
Providers to further encourage on-going surveillance of PSD in the outpatient setting. 
 The long-term viability of this PSD project hinges on ongoing stakeholder feedback and 
support. This was consistently accounted for throughout the entirety of this project and will 
continue beyond its conclusion. Stakeholder engagement was additionally relevant to ensuring 
that the practice change was adopted during the persuasion stage of adoption as discussed by 
Rogers (2003). Giving a voice to all those affected by this project created buy-in that will 
hopefully help sustain the practice change. 
  Three PSD team members who have bought-in and whom have expressed interests in 
taking on the responsibility of ensuring the long-term success of this project include the stroke 
program coordinator, lead neurologist, and the QMC data management expert. Their interest was 
identified using a CDC program evaluation stakeholder interest tool and from ongoing PSD team 
meetings. It will be through their continued support that this project sustains into the future. The 
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longevity of this project has also been bolstered by TJC’s mandate for PSD screening prior to 
discharge. This primary trigger, and impetus for this project, will encourage continued support 
from those in positions to carry out and sustain change within the QMC organization well 
beyond this project’s conclusion. 
Human Subjects Considerations 
 This project was been designed in such a way as to protect the rights of all human 
subjects involved. As an EBP initiative there were no plans to randomize subjects to different 
treatment groups. In forgoing randomization and applying the designed protocol to all eligible 
patients the ethical tenet of justice was maintained. Eligibility was determined by inclusion and 
exclusion criteria that include all patients with a primary diagnosis of stroke and who can 
meaningfully participate in a depression screening as determined by their provider. Reasons a 
patient may not be able to participate in screenings include impaired ability to communicate 
and/or sever cognitive impairment. This PSD screening protocol incorporated the best available 
evidence into a standardized guideline to help ensure all patients receive the same level of care 
ensuring the ethical principle of justice.  
 The PSD protocol maintained the ethical tenet of autonomy for patients and the 
neurology providers performing the screen. Although TJC mandates PSD screening prior to 
discharge, the proposed guideline is not binding for the provider group. They will retain their 
right as autonomous practitioners to screen patients as they see fit moving forward. Likewise, 
patients maintained their autonomy through their right to refuse the PSD screening process. This 
PSD screening protocol additionally adhered to the ethical tenet of non-maleficence, as it did not 
cause any undue harm to stroke patients. The screen was not used to diagnose patients with 
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depression, which could have potentially stigmatized them in the eyes of insurers, family 
members, and outpatient providers.  
 In fulfilling an identified clinical need, this project fulfilled the ethical tenet of 
beneficence. Patients are believed to have benefited from the increased depression surveillance 
through mitigating the potential adverse effects of untreated depression (Towfighi et al., 2017). 
This EBP also did not add any additional risks to patients or providers beyond the provision of 
standard care. During the evaluation phase of this project all patient and provider data was de-
identified by the QMC data expert prior to dissemination to the PSD project team. No 
identifiable data related to this project and its outcomes were stored or are retrievable.  
 To ensure patient and provider’s rights were protected to their fullest extent, the DNP 
student completed a University of Hawaiʻi required Collaborative Institutional Training Initiative 
course in human subjects protection. Additionally, a committee consisting of faculty and clinical 
experts reviewed this project to ensure adequate human subjects protection. A summary of these 
considerations and the project’s intended practice change was submitted to QMC for IRB 
approval. It was their determination that this project represented an EBP without significant risks 
to patients and therefor did not require an IRB approval process. 
Limitations 
 There are many limitations that are inherent to the implementation of an EBP initiative 
and as such apply to this project. The first limitation is that the implementation of this project 
took place in real time, in a fluid environment, and without the ability to control for variables. 
This reduces the overall generalizability of the project’s evaluation findings, even as they may be 
applied to different times of the year at the same facility. The sample for this project was a 
convenience one where inclusion criteria were broad. Additionally, the final sample’s size and 
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characteristics were not known until the end of the four-month implementation phase. It is likely 
that the sample does not adequately represent the characteristics of the larger state population. 
 Another major limitation of this project is the limited evidence to support the use of the 
PHQ-2 in the acute care setting. This instrument is further limited, as the yes/no version used is 
different from the multiple response version studied in most of the literature. As there is no clear 
sensitivity and specificity determined for this instrument in the PSD population, this project’s 
data quality may be diminished. Additional limitations for this project include the heterogeneous 
nature of the group of providers who will be administering the screen, the limited 
implementation period, and the reliance of chart reviews to pull outcomes related data.  
Summary 
 This chapter has detailed the implementation and evaluation plans for this project as well 
as discussed the required resources, plan for dissemination of results, considerations for human 
subjects, and the project’s limitations. The discussions relating to implementation and evaluation 
further described the integration of the three conceptual models being utilized to guide this 
project that include the IOWA model, Rogers Diffusion of Innovation model, and the CDC’s 
framework for program evaluation. The creation of this chapter was a culmination of the efforts 
by the PSD project team in conjunction with ongoing and frequent stakeholder input.  
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Chapter 4. Results 
Objectives 
 The purpose of this evidence-based project was to develop and implement a PSD 
screening protocol at QMC to address the potential psychological complications of having a 
stroke. Triggers for this project included The Joint Commission (TJC) mandate for a prior to 
discharge PSD screening protocol for comprehensive stroke center designation, known 
consequences of untreated PSD related to stroke rehabilitation, and a real gap in behavioral 
health surveillance for stroke patients. Prior to this project QMC’s stroke program did not have a 
standardized screening protocol in place to address the potential for depressive symptoms in their 
stroke patient population. The objectives of this project were to establish an in-patient PSD 
screening protocol at QMC, encourage continuity of PSD screening and care to the outpatient 
setting, and to increase provider comfort discussing and screening for PSD with their patients. 
The following chapter details the final sample characteristics and results of this project’s four-
month interventional period. 
Description of Sample 
 Prior to the initiation of this project’s intervention the core stakeholder group and PSD 
team agreed upon inclusion and exclusion criteria for each sample group. Inclusion criteria for 
the patient group included all those patients that were admitted and discharged with a primary 
diagnosis of stroke from the QMC neurological intensive care units. Exclusion criteria for the 
stroke patients included an inability to participate in the screening per provider judgment. 
Provider reasons for exclusion included an inability to communicate, deficient cognitive ability 
to participate meaningfully in depression screening, or patient refusal. Inclusion criteria for the 
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provider group included designation as a neurology unit provider at QMC. Exclusion criteria 
included those providers from disciplines outside of the neurology department. 
 The final sample of stroke patients captured over the four-month period included 121 
patients of which 35 were removed prior to data analysis. Over the course of this intervention it 
was decided that, in addition to deceased patients, all patients transferred to another acute care 
facility would not be considered for final analysis. This determination was based on the logic that 
those few patients transferred to other facilities were typically in a terminal condition where 
PHQ-2 screenings was unnecessary. In total, 35 patients were removed with 26 patients dying 
prior to discharge and nine transferred to outside facilities. Of the 86 patients retained there was 
a near 1:1 male to female ratio. No additional demographic data was captured due to concerns 
about patient confidentiality. 
 The final sample of providers included 3 neurological physicians and 9 acute care nurse 
practitioners. All 12 providers were present during the four-month intervention period and each 
was responsible for completing at least one PSD screen. No additional demographic data was 
captured related to the provider group. 
Trend Analysis for Process and Outcome Variables 
 As discussed in chapter three, an impact evaluation of this project was conducted to allow 
the PSD team to determine the effect of the intervention on the target population through an 
analysis of outcomes related data (Center for Disease Control and Prevention, 2014). To bolster 
the validity of the impact evaluation, a process evaluation was also conducted to ensure that the 
protocol was implemented as intended and that the results being gathered were applicable to 
desired outputs (Center for Disease Control and Prevention, 2014). Prior to this project’s 
implementation the core stakeholder group agreed upon definitions related to process and 
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outcomes related variables to ensure accurate data was collected. The final PSD screening data 
totals and each data collection period’s data can be found in Appendix E. 
Process Variables 
 This project’s process variables included provider comfort discussing and screening for 
PSD, mid-intervention screening compliance rates, and the accuracy of completed EMR screens. 
Provider comfort discussing PSD as well as provider screening compliance rates were both 
considered process and outcomes related variables and will be discussed as each in the outcomes 
section. 
 Accuracy. To ensure this project’s protocol was being implemented as intended the PSD 
data collection team scored each provider’s EMR screen as either complete or incomplete. A 
complete score meant that the provider followed the appropriate PSD algorithm correctly from 
beginning to end. If the provider missed a step or omitted any documentation, regardless of 
PHQ-2 results, then the screen was scored as incomplete. The overall accuracy of all screens was 
determined by dividing the number of complete screens by the number of screens attempted. 
After the initial six weeks of the interventional period the provider group had an accuracy rate of 
70%. Over the next four weeks their accuracy improved slightly to 75%. The two weeks 
following showed a jump in accuracy to 100%, which the team was then able to maintain 
through the final four weeks.  
 Analysis of the provider’s documentation allowed the PSD team to identify common 
errors that led to the initial low accuracy rates. The two main errors were the deletion of protocol 
sections by the providers and a failure to document reasons for not providing patient education. 
After reviewing and comparing the PSD protocol algorithm with the protocol in the EMR the 
PSD team was able to better understand the providers’ logistical problems. Instructions about 
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where to go from each step were unclear and there was no option or instructions related to 
documenting reasons for not competing a section of the protocol. These uncertainties were 
removed in an updated version of the protocol, which had a significant effect as evidenced by the 
eventual jump mid intervention to 100% accuracy of all screens attempted. 
Outcome Variables 
 Outcome variables for this project included provider comfort discussing and screening 
for PSD, provider screening compliance rates, PHQ-2 results, and Queen’s Clinically Integrated 
Physician Network (QCIPN) screening rates. Each will be discussed separately.  
 Provider Comfort. During an early pre-intervention round table discussion with QMC 
neurology unit providers it was determined that there was some unease discussing and screening 
for PSD. This led to an initial email to the provider team that contained an educational PSD 
handout that included information about PSD, its potential for significant harm, and tips for 
discussing it with their patients. Attached at the end of the email were instructions to complete a 
pre-intervention survey that was meant to assess a new baseline comfort in screening for PSD in 
the provider sample group. The initial four-question survey was completed by 10 of the 12 
providers.  
 The first question read, on a scale from 0 to 5 how satisfied are you with the current 
screening process. The average response was 2.89. The second question read, on a scale from 0 
to 5 how confident are you in using the PHQ-2 to screen for PSD? The average response was 
3.63. The third question read, on a scale from 0 to 5 how comfortable are you discussing the 
potential for the development of PSD with stroke patients? The average response was 3.78. The 
final question read, do you feel the screening process in place now is adequate in detecting PSD 
risk in stroke patients? The majority, at 66%, responded no. This survey gave the implementation 
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team an idea of where the providers were at with screening for PSD and how much more 
provider education would be beneficial to the overall success of the project’s main objectives.  
 At the conclusion of the four-month interventional period a second survey was sent to the 
provider staff that was identical to the first. This allowed the PSD team to quantitatively assess 
whether the intervention itself and their provider education efforts had any effect on the project 
objective of increasing provider comfort assessing for PSD. Results of the second survey showed 
a positive effect across all questions although the response rate was much lower with just 5 out 
12 responses. The first question again read, on a scale from 0 to 5 how satisfied are you with the 
current screening process. The average response was 4. The second question read, on a scale 
from 0 to 5 how confident are you in using the PHQ-2 to screen for PSD? The average response 
was 4.2. The third question read, on a scale from 0 to 5 how comfortable are you discussing the 
potential for the development of PSD with stroke patients? The average response was 4. The 
final question read, do you feel the screening process in place now is adequate in detecting PSD 
risk in stroke patients? The majority, at 80%, responded yes. 
 During implementation regular communication between the PSD team and provider staff 
took place during staff meetings, floor discussions, and emails. This helped reinforce the 
educational material presented to the providers about PSD and gave the providers a chance to 
offer feedback about the new screening process. Additionally, the PSD educational pamphlet 
given to all stroke patients was designed so that a provider could use it as a prompt for initiating 
a discussion about PSD and as a transition into the PHQ-2. Comfort with the new screening 
protocol and in discussing PSD increased steadily throughout the intervention as evidenced by 
provider feedback, screening accuracy rates, screening compliance, and final survey results. The 
ongoing assessment of provider comfort with PSD and PSD screening allowed the PSD team to 
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ensure that their protocol was being implemented as intended. The final assessment of this 
variable additionally allowed the PSD team to determine the impact of their interventions on one 
of the project’s main objectives. 
 Compliance Rates. At four points during the four-month intervention period a data 
analysis was conducted to determine periodic screening compliance rates. To aid in the 
reinvention process it was considered necessary to track compliance throughout this intervention. 
Periodic compliance checks allowed the PSD to identify common errors or omissions in the new 
screening process, which further allowed the team to augment the protocol and/or provide further 
education as needed. Compliance rates were determined by dividing the number of eligible 
patients screened by the number of eligible patients. The first data analysis was conducted after 
the initial six weeks of the interventional period and showed a compliance rate of 79% out of 29 
data entries. The next four weeks showed a compliance rate of 87% out of 23 data entries. The 
two weeks following had a compliance rate of 90.5% out of 21 data entries. The final four weeks 
of the intervention showed a compliance rate of 93% out of 14 data entries.  
 Chart reviews of each patient screened allowed the PSD team to identify reasons patients 
were not being screened appropriately. The number one reason was that patients were being 
screened with an outdated screening tool located in the QMC EMR. Although providers were 
screening their patients for depression they were doing so without the new protocol and so these 
screens were marked as misses. The only other reason identified was that providers were simply 
not offering or not documenting any screening for depression. Ongoing reinforcement with the 
provider team during regularly scheduled meetings was used to mitigate these errors. As the 
protocol was fine-tuned throughout the interventional period and as providers got more 
comfortable with the screening process the rate of compliance steadily increased to above the 
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target goal. The final average compliance rate over the four-month interventional period was 
86%. By the final six weeks, however, the team elevated their compliance rate to just above the 
90% goal for this project’s compliance objective. 
 PHQ-2 Results. The patient-centered focus of the screening protocol implemented at 
QMC during this project was the administration of the PHQ-2 to detect early depressive 
symptoms in stroke patients. Of the 86 patients that were included in data analyses, 74 were 
screened with the PSD screening protocol. Of those 74 patients, 13 were deemed inappropriate 
for the PHQ-2 due to their inability to participate per provider judgment. Provider reasons for 
exclusion included lack of cognitive ability, aphasia, and patient refusal. Of the 61 patients 
screened with the PHQ-2, 7 screened positive and 54 screened negative for depressive 
symptoms. The final prevalence rate of depressive symptoms for this sample of stroke patients 
was 11.5%. Of the 7 patients that screened positive for depressive symptoms, 3 were initiated on 
an SSRI.  
 Outpatient Screening. To encourage continuity of care the PSD team had hoped to 
measure the effects of outpatient outreach efforts in the QCIPN community on 90-day post 
stroke discharge screening rates. Project interventions aimed at increasing QCIPN outpatient 
screening rates included a August 2017 PSD webinar for all QCIPN providers, patient discharge 
summaries with PSD screening results, and the direct communication of all positive PHQ-2 
screens to QCIPN patient providers. Unfortunately, due to a lag in claims data and a change to 
patient data storage all of this information is not yet available for the period this intervention 
took place. In 2016 QCIPN providers performed zero 90-day post discharge depression screens 
for stroke patients. Data for 2017 was only available through June and revealed a 90-day post 
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discharge screening rate for stroke patients of 11.6%. Although the modest increase in screening 
rates is reassuring for stroke patients it cannot be attributed to this project’s efforts. 
Evolution of Project 
 This project began with the simple idea of adding a layer of behavioral health screening 
for stroke patients that at the time was missing. This led to an initial literature search and review 
that then yielded a recommendation for a change in practice. Operationalizing the practice 
change went smoothly considering that behavioral change is a difficult endeavor under most 
circumstances. A discussion of the expected versus actual outcomes as well as what aided and 
hindered this project follows. 
Expected vs. Actual Outcomes 
 The expected versus actual outcomes of this project were more or less congruent with the 
exception of the PHQ-2 results. In the literature, 33% is the accepted prevalence rate for 
depressive symptoms following a stroke at any time during recovery (Hacket et al., 2005). The 
PSD team expected to show similar prevalence rates in their QMC sample, however, this was not 
the case. The prevalence rate was much lower at 11.5%.  
Facilitators 
 This project benefited tremendously from the efforts of a small team of QMC providers 
that were dedicated to fixing a recognized gap in care for their stroke patients. The open culture 
of change that this team already embodied prior to this project allowed for a smooth integration 
of the proposed screening protocol. Team leadership by the stoke program coordinator further 
assisted the rapid dissemination and adoption of this project’s innovation. Regular 
communication between the stroke program coordination, PSD team, and neurology providers 
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was instrumental in the rapid achievement of the project objectives related to accuracy of screens 
and provider compliance rates.  
Barriers 
 The only major barrier to the implementation and success of this project was the 
laborious process of changing the QMC EMR. Making permanent changes to the EMR requires 
approval by multiple committees before the act of changing it can even begin. Due to the time 
constraints of this project a permanent change to the EMR was never accomplished. Changes 
were instead created using what are called dot phrases. These dot phrases are short phrases that 
when entered into a text box on the EMR loads a preset protocol. This meant that providers had 
to delete old sections of their discharge summaries and replace them with the new protocol using 
dot phrases. Given the difficulty in changing provider behaviors, this added layer of complexity 
was a significant barrier to the success of this project. Fortunately, the project’s facilitators 
overcame this barrier and the project was a success. 
Summary 
 This project set out with intentions to establish an in-patient PSD screening protocol at 
QMC, encourage continuity of PSD screening and care to the outpatient setting, and to increase 
provider comfort discussing and screening for PSD with their patients. It did so with the creation 
of a PSD screening protocol at QMC that was used to screen 86 patients over four months. This 
chapter reflects the results of the data gathered during the four-month implementation period. 
Process variables for this project helped the PSD team ensure that their protocol was being 
implemented as intended and that the data gathered was accurate. Outcome variables for this 
project helped the PSD to identify the impact of their interventions and whether the project 
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objectives were met. A discussion and interpretation of this project’s findings will follow in the 
next chapter. 
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Chapter 5. Discussion 
Interpretation of Findings 
 This project’s objectives included establishing an in-patient PSD screening protocol at 
QMC, encouraging continuity of PSD screening and care to the outpatient setting, and increasing 
provider comfort discussing and screening for PSD with their patients. Chapter four presented an 
analysis of the data collected during this project’s implementation period. This chapter will focus 
on the interpretation of that analysis and what it means in relation to the project’s objectives, 
stroke patient care, and the larger body of evidence related to PSD.  
Provider Comfort and Compliance 
 Stroke patients are believed to suffer from PSD at a prevalence rate of 33% at any given 
point in time during their recovery (Hacket et al., 2005). Of those patients, it is assumed that 
nearly 80% go undetected and therefore untreated for their depressive symptoms (El Husseini et 
al., 2012). Two potential reasons stroke patients are left untreated for their depressive symptoms 
include that providers are both unaware of PSD as a significant complication of having had a 
stroke and a general lack of discomfort discussing depression with their patients. Both of these 
contributing factors were found to be the case in this project where the provider group expressed 
an initial lack of awareness about PSD and unease about discussing PSD with newly diagnosed 
stroke patients. To eliminate these barriers to adequate behavioral health surveillance 
interventions were designed to educate the provider group. 
 The education and support the provider staff received in relation to PSD led to a steady 
increase in their confidence related to PSD screening. This was evidenced both by their pre and 
post intervention survey responses and their achievement of the project’s compliance goal. By 
project’s end the compliance rate for providers was 93%. This meant that not only were 
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providers screening the majority of their patients but that they were engaging in patient education 
related to PSD as well. By reinforcing the provider’s knowledge base related to PSD, how to 
discuss it, and how to screen for it this project was able to elevate the care stroke patients 
received during the acute care phase of their recovery. This is especially true considering pre 
intervention QMC stroke patients were receiving neither PSD screening nor PSD education. 
Although the evidence base is unclear as to what can help prevent PSD, it is believed here that 
early and ongoing assessment of PSD will be shown to mitigate the potential effects of PSD in 
future research.  
Outpatient Screening Rates 
 It is unfortunate that this work cannot accurately report on the effects of the outpatient 
outreach interventions designed by this project. The lack of follow-up data is related to a lag in 
claims information and a change in the data warehouse used by the QCIPN mid intervention. In 
August 2017 a PSD webinar was offered to all QCIPN providers to enhance their awareness 
about PSD and to introduce them to the new QMC screening process. The hope was that this 
intervention, along with the new discharge summaries and direct provider-to-provider 
communication of all positive screening results, would lead to enhanced outpatient behavioral 
health surveillance for stroke patients.  
 A major objective of this project was to encourage a continuity of care for QMC stroke 
patients as they transitioned out of the acute care setting. This objective was important to the 
PSD project team due to the fact that PSD has been shown to develop at different times for 
different patients during their recovery process over five years post stroke (Towfighi et al., 
2017). Although this objective cannot be confirmed due to a lack of data it is believed that the 
project’s work and future plans of the QMC stroke program will eventually lead to this objective 
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being fulfilled. QMC’s stroke program has already begun to see their discharged stroke patients 
at an in-house stroke patient follow-up clinic. During visits at the stroke program’s follow-up 
clinic patients are screened once again for PSD. Eventually, QMC will be one of the only 
facilities nationally to be able to track PSD data for their own patients as they transition from the 
acute care into the outpatient setting. 
Screening Results 
 The purpose of this project was to establish an in-patient PSD screening protocol at QMC 
to mitigate the potential effects of PSD. This purpose statement was designed based on national 
statistics related to the prevalence and consequences of PSD. Until this project however, no work 
had been done in Hawaiʻi that illustrated the prevalence of PSD in the local population. The 
screening results in this project represent the first glimpse into how many local patients are 
affected by PSD in the acute care phase of their stroke recoveries.  
 Of the 61 patients screened with the PHQ-2 there were 11.5% that screened positive for 
depressive symptoms. This is well below the 33% prevalence rate typically attributed to PSD but 
still shows that PSD is present in the immediate post stroke period. Explanations for the gap in 
prevalence rates include the short interventional period, use of a deficient screening tool, and 
decreasing lengths of stay for stroke patients. The four-month period of data collection may not 
adequately represent the local stroke patient population and their prevalence of PSD. More data 
will need to be collected and analyzed in the future to determine the true prevalence of PSD in 
Hawaiʻi.  
 The yes/no PHQ-2 screening tool utilized in this project has not been as adequately 
validated in the stroke patient population as other screening tools. It is possible that the screening 
tool is deficient in the acute care setting or for stroke patients in general. Finally, the average 
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length of stay for stroke patients during this intervention was 6.3 days. This is considerably 
shorter the average length of stay for stroke patients in the majority of PSD literature (Meader, 
et. al, 2014). It is possible that decreasing hospital stays for stroke patients may somehow 
contribute to a lower diagnostic rate of PSD. 
 The PHQ-2 results from this project show that stroke patients in Hawaiʻi do suffer from 
depressive symptoms following an acute stroke event. Given that prior to this project no 
standardized PSD screenings were offered at QMC it is reasonable to conclude that a gap in 
patient care was fulfilled by this project. Although TJC may eventually repeal their mandate for a 
prior to discharge PSD screening protocol, the results of this project have convinced the stroke 
program coordinator of the ongoing utility of PSD screening. Further research in the area of PSD 
prevention and treatment will be needed to shed light on the exact contribution that early PSD 
screening has on reducing post stroke complications.  
Project Implications for the Doctor of Nursing Practice 
 The American Association of Colleges of Nursing (AACN; 2006) is responsible for 
publishing a comprehensive set of curricula that all DNP programs are expected to provide their 
students. Contained within the curricula are eight DNP essentials that each prospective DNP 
graduate must master by the conclusion of their studies. Detailed below is a description of how 
each of these essentials was addressed by this practice change project. 
Essential I: Scientific Underpinnings for Practice 
 DNP prepared nurses must have the ability to integrate and to draw upon multiple 
scientific disciplines in their practice settings. This is necessitated by the increasing complexity 
of healthcare delivery and the expectation that DNP graduates will seek out leadership positions 
where they will be tasked with systems level change. This particular DNP project drew upon 
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three scientifically based conceptual models to guide each step of the process. The master 
template for this project was taken from the IOWA model of evidenced based practice, which 
details a step-wise guide for translational science within nursing (Titler et al., 2001).  
 Rogers Diffusion of Innovation Theory (2003) is a social science theory that was utilized 
to aid in the dissemination of this project’s proposed intervention. Rogers (2003) social diffusion 
model helped guide this project’s marketing strategies as well as aided in developing strategies to 
include all stakeholders in the design and implementation processes. The final conceptual model 
utilized in this project was the CDC’s program evaluation guide. In utilizing tools and concepts 
from the CDC model this project was able to ensure a high level of quality and validity related to 
the interpretation and dissemination of its findings. This project additionally considered and 
integrated the principles of holistic healthcare, the nursing code of ethics, and concepts from the 
Collaborative Institutional Training Initiative into each step of the process. 
Essential II: Organizational & Systems Leadership for QI & Economics 
 DNP graduates must be able to effectively navigate complex organizational settings and 
to wield systems level leadership to deliver equitable healthcare (AACN, 2006). The design, 
implementation, and evaluation of this project required consideration for the culture, policies, 
and preferences of QMC, the QMC stroke program, the QMC neurological intensive care units, 
and the QMC stroke program’s provider team. This complex web of organizational units 
required the project team’s leadership to demonstrate systems level leadership strategies tailored 
to the specific needs of individual groups. The foundation of this project’s leadership style was 
rooted in ongoing stakeholder engagement. This was done through communication channels 
designed to elicit quality feedback from all those affected by the intervention.  
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 Stakeholder engagement is highlighted in both the IOWA model and the CDC program 
evaluation guide as a means to ensuring buy-in as well as sustainability of practice change 
initiatives (Titler et al., 2001; Center for Disease Control and Prevention, 2014). Stakeholder 
engagement was additionally utilized as a transformational leadership strategy where information 
gained was used to set clear goals, create an emotional connection to the project, encourage 
ongoing commitment, and to draw-upon as well as to build up each person’s contributions. 
Throughout implementation, and with stakeholder engagement, this project’s team successfully 
navigated the implementation of a patient-centered intervention that maintained patient safety 
while being cost-effective and sustainable. 
Essential III: Evidence-Based Practice/Translation Science 
 Evidenced-based practice requires that research be translated into everyday clinical 
practice through an intentional process. The process is often complex and time consuming with 
the result being a significant delay between research findings and integration into practice. 
Integration can be enhanced, however, with the use of an individual trained in translational 
science that utilizes a sound translational model. DNP essential III describes what it means to 
master the translational process as a doctoral nurse and parallels the steps of the IOWA model. 
The first step in the IOWA model is to identify clinical triggers that signal a need for change 
relating to a practice topic (Titler et al., 2001). Once triggers are identified, a practice change 
topic selected, and enough interest gained there remain six steps in the process: 2) forming a 
team, 3) literature search, 4) literature review and critique, 5) practice change recommendation, 
6) piloting the change with evaluation and subsequent full-scale implementation, and 7) 
evaluation of project (Titler et al., 2001). 
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 The IOWA model significantly enhanced this project’s success through its clear step-
wise guide and associated tips for a successful implementation. Within step four of the model 
Melnyk’s Hierarchy of Evidence was utilized to grade and critique all articles found. An 
important component of the translational process is being able to identify quality research so as 
to determine whether the quality and or quantity of content located are sufficient to support a 
practice change. In this project the body of evidence was deemed sufficient to move ahead. Part 
of the decision to move forward was based on the fact that the literature clearly identified gaps in 
care at QMC and potential benefits to a change in practice. This project concluded with a final 
dissemination of all findings to QMC and the public so that its data could feed back into the 
research being done on PSD. 
Essential IV: Information Systems/Technology 
 In our modern era of information and technological systems it is imperative that a DNP 
prepared nurse master the use of technology in their practice setting (AACN, 2006). This project 
drew heavily upon the electronic medical record (EMR) system at QMC for the design, 
implementation, and evaluation of the completed intervention. During the design phase it was 
necessary for the project team to become acquainted with the EMR as it was designed and how it 
fit into the workflow of the provider staff. This guided both the final decision on which screening 
instrument to utilize and how to integrate it into the EMR. The yes/no version of the PHQ-2 was 
eventually chosen, as it was simple, easy to integrate into the EMR, and was acceptable by the 
provider staff. 
 During implementation and evaluation the EMR provided the data the team needed for 
reinvention and to draw final conclusions about the project. As issues arose during 
implementation related to data collection, the PSD screening algorithm was tweaked to better 
 72 
suit the providers and the EMR. DNP prepared nurses must also be ready to address 
technological barriers. For instance, at QMC the process of making permanent changes to the 
EMR is timely and requires multiple committees to sign off on a final product. As this did not 
work for this project’s timeline, temporary changes were made using dot phrases by the provider 
staff. This was problematic at first as it greatly increased the complexity of the expected behavior 
change and led to an initially low compliance rate. In addition to the EMR, secure messaging 
systems were utilized to communicate between providers and with patients. 
Essential V: Health Care Policy & Ethics 
 DNP prepared nurses are expected to advocate for policy changes at any and all levels 
related to the delivery of just and equitable healthcare. This includes advocating for the closing 
of any gaps in care identified. In the case of this project the DNP student and project team 
identified a significant gap in care for stroke patients related to the potential psychological 
complications of having had a stroke. One third of stroke patients are likely to experience 
depressive symptoms at some point following their stroke within five years (Hacket et al, 2005). 
Of those patients nearly 80% will be left undetected and therefore untreated (El Husseini, 2012). 
The project team further identified that untreated depression following a stroke is related to 
poorer health related outcomes including a 3.4 times increase in mortality (Paolucci, 2008).  
 Although a prior to discharge PSD depression screening program was mandated by TJC 
for comprehensive stroke center status at QMC, the project team advocated for outpatient 
monitoring to be included in the project. This was accomplished through reaching out to the 
QMC outpatient provider population via a PSD webinar, incorporating a direct provider 
communication tool into the screening process, and through ongoing QMC outpatient stroke 
clinic screenings. The mandate for in-patient screenings will likely be discontinued by the TJC in 
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the near future but the stroke program at QMC plans to continue the screening process. A big 
goal of this project was that awareness of PSD will be enhanced through the efforts of this 
project and that ongoing screenings will become more common statewide. 
Essential VI: Inter-professional Collaboration 
 The core project team involved in this intervention consisted of a lead DNP student, 
registered nurses, advanced practice registered nurses, and physicians. This interdisciplinary 
team was able to effectively communicate their input throughout the process of this project. 
Collaboration among the disciplines enhanced the project’s overall success and contributed to the 
probable sustainability of the intervention. Both communication and collaboration were 
enhanced with periodic team meetings, online surveys, and group emails. Team leadership 
actively included each discipline throughout the project’s life including the evaluation of the 
final data results. Beyond the core team, updates and final results of the project were 
communicated to a much larger multi-disciplinary stroke team that has regularly scheduled 
monthly meetings as part of the QMC comprehensive stroke program. 
Essential VII: Prevention and Population Health 
 The AACN describes essential VII as the ability for DNP prepared nurse to analyze bio 
statistical and epidemiological data in an effort to design healthcare initiatives that address a 
broad range of sociocultural issues related to specific populations (AACN, 2006). The population 
in this project included patients who were diagnosed with having had a stroke and the goal of the 
project was the secondary prevention of PSD in this population. After analyzing the available 
data the project team made the decision to design a healthcare initiative to address the gap in care 
previously discussed. Designing a PSD screening protocol at QMC required the team to have a 
multicultural approach. As QMC cares for patients of many cultural backgrounds it was 
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important to integrate culturally sensitive language into the screening and educational process of 
the project. The final intervention included translated PSD educational handouts as well as 
encouraged the provider’s to use the hospital’s translator services. 
Essential VIII: Advanced Nursing Practice & Education 
 The final AACN essential of DNP practice details what it means to master the delivery of 
advanced primary healthcare. This essential includes the ability of a DNP prepared nurse to 
conduct a comprehensive history and physical, design therapeutic interventions, maintain 
therapeutic relationships with patients, demonstrate advanced levels of clinical judgment, 
educate fellow nurses, guide patient’s through complex healthcare systems, and to navigate the 
complexities of healthcare themselves (AACN, 2006). This project required the use of each of 
these skills as patients were initially assessed for depression, prescribed therapeutic 
interventions, and were followed up with after discharge. The delivery of PSD screening and 
care required the nurse to demonstrate a strong understanding of the complexities of 
comorbidities, the healthcare system as it involves navigating specialist and case management, 
and the ability to educate fellow nurses about PSD. 
Plans for Dissemination 
 The final step in the IOWA model for evidenced based practice is the dissemination of a 
practice change project’s results (Titler et al., 2001). This step is critical so that institutions, 
including the one where a practice change was initiated, may benefit from the lessons learned 
during the implementation process. Although no two facilities are alike, the sharing of 
information related to practice change initiatives benefits the whole healthcare community. As 
for QMC, the dissemination of this project’s results are critical to their comprehensive stroke 
certification process. On Febuary 1st, 2018 the results of this project will be presented to the 
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QMC multi-disciplinary stroke program team. By March of 2018 the results of this project will 
be presented to the University of Hawaiʻi community as well as to the local community via an 
open attendance forum. A final dissemination of this project’s results will be made available in 
an article published in a national journal on evidence-based practice and stroke related care.  
Summary 
 This chapter reflects the interpretation of this project’s findings, a relation of this project 
to the DNP essentials, and a timeline for the dissemination of this project’s results. The purpose 
and first objective of this project was fulfilled as a PSD screening protocol was created and 
implemented within the QMC neurological intensive care units. This project was additionally 
able to meet its objective of improving provider comfort discussing and screening for PSD. Due 
to a lack of follow-up data the final objective of establishing continuity in care for stroke patients 
related to their behavioral health was unfortunately not directly met. Results from the PHQ-2 
screens show that PSD is present in the Hawaiʻi stroke patient population. Although the exact 
effects of early detection for PSD are unknown this project’s team hopes that it has helped start 
the conversation of how to mitigate the effects of PSD through early and ongoing screening. 
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Appendix A 
Table 1 
Post Stroke Depression Screening Instruments 
Screening Instrument(s) Reference 
HADS, BDI-II, BDI, WDI, GHQ, WSRS, GDS, BASDEC, 
SADQ-H 
Bennett, H. & Lincoln, N. 
SADQ-H, SODS, VAMS, VASES, HADS Bennett, H., Thomas, S., Austen, R., Morris, & Lincoln, N. 
BDI, HDRS, VAMS, Clinical Global Impression Berg, A., Lonnqvist, J., Palomaki, H., & Kaste, M. 
PHQ-2, PHQ-9 de Man-van Ginkel, J., Gooskens, f., Schepers, V., Schuurmans, 
M., Lindeman, E., & Hafsteinsdottir 
PHQ-2, PHQ-2 de Man-van Ginkel, J., Hafsteinsdottir, T., Lindeman, E., Burger, 
H., Grobbe, D., & Schuurmans, M. 
SADQ H10, BASDEC Hacker, V., Stark, D., & Thomas, S. 
WDI, BDI, GDS, HADS, MADRS, ZDS, PSE-8, CES-D,  
GHQ-28 
Hackett, M., Yapa, C., Parag, C., & Anderson, C. 
HADS, PHQ-9, PHQ-2, BDI, VAMS Hollender, K. 
PHQ-8 Husseini et. al 
BDI, HADS-D, HAMD, MADRS Kang, H. et. al 
PHQ-8 Karamchandani et. al 
GDS-15 Lewis-Richter, A., Volz, M., Jobges, M., & Werheid, K. 
BDI, PHQ-9, PHQ-2, GHQ-12, GHQ-28, CES-D, GDS,  
GDS-15, ZDS, HADS-D, HDRS 
Meader, N., Moe-Byren, T., Llewellyn, A., & Mitchell, A. 
PHQ-9, PHQ-2, HADS, BDI-II, DT, K-10 Turner, A., Hambridge, J.m White, J., Carter, G., Clover, K., 
Nelson, L., & Hackett, M. 
PHQ-9 Williams, L., Brizedine, E., Plue, L., Bakas, T., Tu, W., & 
Kroenke, K. 
Note. BASDEC, Brief Assessment Schedule Depression Cards; BDI, Becks Depression Inventory; CES-D, Center for Epidemiological Studies - 
Depression; DT, Distress Thermometer; GDS-15, Geriatric Depression Screen; GHQ-12/28, General Health Questionnaire; HADS-D, Hospital 
Anxiety Depression Scale - Depression; HAMD, Hamilton Depression Rating Scale; HDRS, Hamilton Depression Rating Scale; K-10, Kessler 
10; MADRS, Montgomery-Asberg Depression Scale; PHQ-2, Public Health Questionnaire 2 item; PHQ-8, Public Health Questionnaire 8 item; 
PHQ-9, Public Health Questionnaire 9 item; PSE, Present State Examination; SADQ H10, Stroke Aphasic Depression Questionnaire 10 item; 
SODS, Signs of Depression Scale; VAMS, Visual Analogue Mood Scale; VASES, Visual Analogue Self-Esteem Scale; WDI, Wakefield 
Depression Inventory; WSRS, Wimbeldon Self-Report Scale; ZDS, Zung Depression Scale 
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Appendix B 
STROKE DEPRESSION SCREENING 
 
Step 1: Can patient meaningfully participate in PSD screen? (Y/N)  
If NO, leave reason(s) for exclusion and discontinue protocol: 
 Severe cognitive disability, inability to communicate, refusal,  
 other (document reason) 
 
Step 2: Reviewed PSD/SSRI handout with patient and/or patient’s family. (Y/N) 
If NO, leave reason(s) for not completing education: 
 Interpreter not available, handout unavailable, refusal,  
 other (document reason) 
 
Step 3: Administer PHQ-2 
 
PHQ-2: 
1) In the previous two weeks have you experienced little interest or pleasure in doing things once 
enjoyable? (Y/N) 
 
2) In the previous two weeks have you felt down, depressed, or hopeless? (Y/N) 
 
 If both answers are NO then skip to Step 5 
 
If answer to either question if YES ask: 
Do you believe you would benefit from an SSRI (antidepressant) prescription? (Y/N) 
 
Step 4: SSRI prescribed? (Y/N) 
 
Step 5: In addition to discharge summary, plan communicated with patient’s PCP via:  
Epic Inbox, phone, fax, other (document method) 
 
Post stroke depression is the number one psychiatric complication following stroke with 33% of 
patients developing depression at some point during their recovery.  
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Appendix C 
 
	
Life	After	Stroke:	Facts	and	Tips	about	Sadness	
		 After	having	a	stroke,	many	people	find	it	difficult	to	express	the	many	feelings	they	have.	Many	of	those	feelings	are	related	to	the	normal	and	healthy	process	of	grieving	the	physical	and	mental	function	that	may	have	been	lost.	Working	through	grief	and	sadness	is	good	for	you,	however	if	those	sad	feelings	last	for	a	long	time	or	get	worse	then	your	overall	health	and	wellbeing	can	be	harmed.		 	
Post	Stroke	Depression	Facts	
	
• Up	to	1/3	of	all	stroke	survivors	get	depressed	sometime	after	their	stroke.	
• Depressive	symptoms	may	happen	immediately	following	a	stroke,	during	rehabilitation/recovery,	or	even	years	later.	
How	Can	Depression	or	Persistent	
Negative	Emotions	Affect	Your	Life?		
• Slow	down	and/or	stop	your	rehabilitation	and	subsequent	recovery.	
• Lower	your	quality	of	life.	
• Increase	your	chances	of	complications,	having	another	stroke,	or	death.	
Signs	of	Depression		
	
• Feeling	extremely	sad	or	“empty”	most	of	the	time	
• Loss	of	interest	or	pleasure	in	activities	once	enjoyed.	
• Fatigue	or	feeling	“slowed	down”	beyond	new	changes	linked	to	the	stroke.	
• Sudden	trouble	sleeping	or	sleeping	too	much.	
• Sudden	change	in	appetite.	
• Increasing	inability	to	concentrate,	remember,	or	make	decisions	like	you	used	to	easily.	
• Feeling	worthless	or	helpless	
• Strong	feelings	of	guilt	
• Ongoing	thoughts	of	death	or	suicide,	even	planning	a	suicide.	
• Crying	all	the	time	
What	Can	Be	Done	to	Help?	
	Overcoming	the	challenges	of	your	recovery	from	a	stroke	and	feelings	of	depression	can	be	improved	when	you:		
• Discuss	how	you	feel	with	your	family,	friends,	counselor,	and/or	primary	care	provider.		
• Consider	taking	medications	for	depression,	research	has	shown	that	they	may	improve	a	stroke	patient’s	recovery	of	lost	physical	function	through	improved	mood.	Speak	with	your	provider	about	the	benefits	of	such	medications.	
• Spend	time	with	the	people	you	enjoy	most.	
• Seek	help	immediately	if	you	or	your	family	recognizes	the	signs	of	depression	presented	above.		
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Appendix D 
 
Advanced Disease-Specific Care Certification Requirements for Comprehensive Stroke 
Center (CSC) 
 
A link to the full set of Advanced Disease-Specific Care Certification Requirements for CSC can 
be found here, http://www.jointcommission.org/assets/1/18/dsc_csc_chap.pdf - 
http://www.jointcommission.org/assets/1/18/dsc_csc_chap.pdf 
  
 PSD specific requirement related to this project: CSC Requirement: DSDF 2, EP 4, d- 
The patient is assessed to identify cognitive decline, depression and other social issues prior to 
discharge. (Note: This requirement is not applicable to comatose patients.) 
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Appendix E 
 
Data Summary for data between July 31st and September 11th 
 
Total Data Entries Kept: 29 
 
Of 29 data entries kept, 
 
Patients not screened: 6 
- 3 used incorrect protocol 
- 1 stand-alone note 
- 2 unknown 
 
Patients screened: 23 
- 16 screens complete 
- 7 screens incomplete  
 
Screen results, 
- 2 positive screens 
- 16 negative screens 
- 5 patients could not participate 
 
SSRI prescription 
- NO DATA 
 
Summary 
Compliance Rate (# of eligible patients screened / # eligible patients: 79% 
 
Accuracy (# screens completed appropriately / # screens completed):  70% 
 
Positive PHQ-2 Rate (# positive screens / # screens): 9% 
 
Adjusted Positive PHQ-2 Rate (# positive screens / # screens minus those that could not 
participate in PHQ-2): 11% 
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Appendix E (Continued) 
 
 
Data between September 12th and October 16th 
 
Total Data Entries Kept: 23 
 
Of 23 data entries kept, 
 
Patients not screened: 3 
Reason not screened, 
- 2 used wrong protocol 
- 1 deleted protocol from d/c summary 
 
Patients screened: 20 
- 15 screens complete 
- 5 screens incomplete  
 
Screen results, 
- 2 positive screens 
- 15 negative screens 
- 2 patients could not participate 
- 1 missing data 
 
SSRI prescription 
- 2 continued current SSRI script 
- 1 started new SSRI script 
 
*Outliers (two incorrect protocols used) 
- 1 screened positive and was given an SSRI script 
- 1 screened negative 
 
Summary 
 
Compliance Rate (# of eligible patients screened / # eligible patients: 87% 
 
Accuracy (# screens completed appropriately / # screens completed):  75% 
 
Positive PHQ-2 Rate (# positive screens / # screens): 9% 
 
Adjusted Positive PHQ-2 Rate (# positive screens / # screens minus those that could not 
participate in PHQ-2): 12% 
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Appendix E (Continued) 
 
 
Data Summary for data between October 17th and November 7th 
 
Total Data Entries: 21 
 
Of 21 data entries kept, 
 
Patients not screened: 2 
- 2 used incorrect protocol 
 
Patients screened: 19 
- 19 screens complete 
- 0 screens incomplete  
 
Screen results, 
- 1 positive screens 
- 14 negative screens 
- 4 patients could not participate 
 
SSRI prescription 
- 17 not prescribed 
- 1 continued current SSRI script 
- 1 started new SSRI script 
 
Summary 
Compliance Rate (# of eligible patients screened / # eligible patients: 90.5% 
 
Accuracy (# screens completed appropriately / # screens completed):  100% 
 
Positive PHQ-2 Rate (# positive screens / # screens): 5% 
 
Adjusted Positive PHQ-2 Rate (# positive screens / # screens minus those that could not 
participate in PHQ-2): 6.5% 
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Appendix E (Continued) 
 
Data Summary for data between November 8th and December 1st 
 
Total Data Entries: 14 
 
Of 14 data entries kept, 
 
Patients not screened: 1 
- 1 used incorrect protocol 
 
Patients screened: 13 
- 13 screens complete 
- 0 screens incomplete  
 
Screen results, 
- 2 positive screens 
- 8 negative screens 
- 3 patients could not participate 
 
SSRI prescription 
- 13 not prescribed 
- 0 continued current SSRI script 
- 0 started new SSRI script 
 
Summary 
Compliance Rate (# of eligible patients screened / # eligible patients: 93% 
 
Accuracy (# screens completed appropriately / # screens completed):  100% 
 
Positive PHQ-2 Rate (# positive screens / # screens): 15.5% 
 
Adjusted Positive PHQ-2 Rate (# positive screens / # screens minus those that could not 
participate in PHQ-2): 20% 
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Appendix E (Continued) 
 
Data Summary for data between July 31st and December 1st 
 
 
Total Patient Charts Reviewed: 121 
 
Total data entries kept for analysis: 86 
 
Total data entries removed: 35 
 - 26 patients deceased 
 - 5 transferred to hospice care 
 - 4 patients transferred to Kaiser in critical care 
 
Of 86 data entries kept, 
 
Patients not screened: 12 
- 7 used incorrect protocol 
- 5 protocols missing or mostly deleted 
 
Patients screened: 74 
- 62 screens complete 
- 12 screens incomplete  
 
Screen results, 
-  7 positive screens 
-  54 negative screens 
- 13 patients could not participate 
 
SSRI prescription 
- 67 not prescribed 
- 4 continued current SSRI script 
- 3 started new SSRI script 
 
Summary 
Compliance Rate (# of eligible patients screened / # eligible patients: 86% 
 
Accuracy (# screens completed appropriately / # screens completed):  84% 
 
Positive PHQ-2 Rate (# positive screens / # screens): 9.5% 
 
Adjusted Positive PHQ-2 Rate (# positive screens / # screens minus those that could not 
participate in PHQ-2): 11.5% 
 
Gender Breakdown: 42 Females and 44 Males 1:1 
 
